

QAZI

Connecting via Winsock to STN

Welcome to STN International! Enter x:x

LOGINID:sssptal202sxq

PASSWORD:

TERMINAL (ENTER 1, 2, 3, OR ?):2

\* \* \* \* \* Welcome to STN International \* \* \* \* \*

NEWS	1		Web Page URLs for STN Seminar Schedule - N. America
NEWS	2		"Ask CAS" for self-help around the clock
NEWS	3	OCT 23	The Derwent World Patents Index suite of databases on STN has been enhanced and reloaded
NEWS	4	OCT 30	CHEMLIST enhanced with new search and display field
NEWS	5	NOV 03	JAPIO enhanced with IPC 8 features and functionality
NEWS	6	NOV 10	CA/Capplus F-Term thesaurus enhanced
NEWS	7	NOV 10	STN Express with Discover! free maintenance release Version 8.01c now available
NEWS	8	NOV 20	CAS Registry Number crossover limit increased to 300,000 in additional databases
NEWS	9	NOV 20	CA/Capplus to MARPAT accession number crossover limit increased to 50,000
NEWS	10	DEC 01	CAS REGISTRY updated with new ambiguity codes
NEWS	11	DEC 11	CAS REGISTRY chemical nomenclature enhanced
NEWS	12	DEC 14	WPIDS/WPINDEX/WPIX manual codes updated
NEWS	13	DEC 14	GBFULL and FRFULL enhanced with IPC 8 features and functionality
NEWS	14	DEC 18	CA/Capplus pre-1967 chemical substance index entries enhanced with preparation role
NEWS	15	DEC 18	CA/Capplus patent kind codes updated
NEWS	16	DEC 18	MARPAT to CA/Capplus accession number crossover limit increased to 50,000
NEWS	17	DEC 18	MEDLINE updated in preparation for 2007 reload
NEWS	18	DEC 27	CA/Capplus enhanced with more pre-1907 records
NEWS	19	JAN 08	CHEMLIST enhanced with New Zealand Inventory of Chemicals
NEWS	20	JAN 16	CA/Capplus Company Name Thesaurus enhanced and reloaded
NEWS	21	JAN 16	IPC version 2007.01 thesaurus available on STN
NEWS	22	JAN 16	WPIDS/WPINDEX/WPIX enhanced with IPC 8 reclassification data
NEWS EXPRESS			NOVEMBER 10 CURRENT WINDOWS VERSION IS V8.01c, CURRENT MACINTOSH VERSION IS V6.0c(ENG) AND V6.0Jc(JP), AND CURRENT DISCOVER FILE IS DATED 25 SEPTEMBER 2006.
NEWS HOURS			STN Operating Hours Plus Help Desk Availability
NEWS LOGIN			Welcome Banner and News Items
NEWS IPC8			For general information regarding STN implementation of IPC 8
NEWS X25			X.25 communication option no longer available

Enter NEWS followed by the item number or name to see news on that specific topic.

10782337

QAZI

All use of STN is subject to the provisions of the STN Customer agreement. Please note that this agreement limits use to scientific research. Use for software development or design or implementation of commercial gateways or other similar uses is prohibited and may result in loss of user privileges and other penalties.

\* \* \* \* \* STN Columbus \* \* \* \* \*

FILE 'HOME' ENTERED AT 13:30:52 ON 19 JAN 2007

=> EGISTRY

EGISTRY IS NOT A RECOGNIZED COMMAND

The previous command name entered was not recognized by the system.  
For a list of commands available to you in the current file, enter  
"HELP COMMANDS" at an arrow prompt (=>).

=> FILE REGISTRY

COST IN U.S. DOLLARS	SINCE FILE ENTRY	TOTAL SESSION
FULL ESTIMATED COST	0.21	0.21

FILE 'REGISTRY' ENTERED AT 13:31:08 ON 19 JAN 2007

USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.  
PLEASE SEE "HELP USAGETERMS" FOR DETAILS.  
COPYRIGHT (C) 2007 American Chemical Society (ACS)

Property values tagged with IC are from the ZIC/VINITI data file  
provided by InfoChem.

STRUCTURE FILE UPDATES: 18 JAN 2007 HIGHEST RN 917867-30-2  
DICTIONARY FILE UPDATES: 18 JAN 2007 HIGHEST RN 917867-30-2

New CAS Information Use Policies, enter HELP USAGETERMS for details.

TSCA INFORMATION NOW CURRENT THROUGH June 30, 2006

Please note that search-term pricing does apply when  
conducting SmartSELECT searches.

REGISTRY includes numerically searchable data for experimental and  
predicted properties as well as tags indicating availability of  
experimental property data in the original document. For information  
on property searching in REGISTRY, refer to:

<http://www.cas.org/ONLINE/UG/regprops.html>

=> S 235108-14-2/RN

L1 1 235108-14-2/RN

=> S 213319-29-0/RN

L2 1 213319-29-0/RN

=> S 2133250-70-5/RN

L3 0 2133250-70-5/RN

=> S 213250-70-5/RN

L4 1 213250-70-5/RN

10782337


QAZI

=> D L1 AND L2 AND L4  
L2 IS NOT VALID HERE  
For an explanation, enter "HELP DISPLAY".

=> D L1

L1 ANSWER 1 OF 1 REGISTRY COPYRIGHT 2007 ACS on STN  
RN 235108-14-2 REGISTRY  
ED Entered STN: 26 Aug 1999  
CN 19-Nor-9,10-secocholesta-5,7-diene-1,3,25-triol, 2-methylene-,  
(1 $\alpha$ ,3 $\beta$ ,7E,14 $\beta$ )- (9CI) (CA INDEX NAME)  
FS STEREOSEARCH  
MF C27 H44 O3  
SR CA  
LC STN Files: CA, CAPLUS, TOXCENTER, USPATFULL

Absolute stereochemistry.  
Double bond geometry as shown.



\*\*PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT\*\*

1 REFERENCES IN FILE CA (1907 TO DATE)  
1 REFERENCES IN FILE CAPLUS (1907 TO DATE)


=> D L2

L2 ANSWER 1 OF 1 REGISTRY COPYRIGHT 2007 ACS on STN  
RN 213319-29-0 REGISTRY  
ED Entered STN: 28 Oct 1998  
CN 19-Nor-9,10-secocholesta-5,7-diene-1,3,25-triol, 2-methylene-,  
(1 $\alpha$ ,3 $\beta$ ,7E)- (9CI) (CA INDEX NAME)  
OTHER NAMES:  
CN 1,3-Cyclohexanediol, 2-methylene-5-[(2E)-[(1R,3aS,7aR)-octahydro-1-[(1R)-5-hydroxy-1,5-dimethylhexyl]-7a-methyl-4H-inden-4-ylidene]ethylidene]-, (1R,3R)-  
FS STEREOSEARCH  
MF C27 H44 O3  
SR CA  
LC STN Files: CA, CAPLUS, CASREACT, TOXCENTER, USPAT2, USPATFULL

Absolute stereochemistry.  
Double bond geometry as shown.

10782337

QAZI



\*\*PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT\*\*

29 REFERENCES IN FILE CA (1907 TO DATE)  
29 REFERENCES IN FILE CAPLUS (1907 TO DATE)

=> D L4

L4 ANSWER 1 OF 1 REGISTRY COPYRIGHT 2007 ACS on STN

RN 213250-70-5 REGISTRY

ED Entered STN: 27 Oct 1998

CN 19-Nor-9,10-secocholesta-5,7-diene-1,3,25-triol, 2-methylene-,  
(1 $\alpha$ ,3 $\beta$ ,7E,20S)- (9CI) (CA INDEX NAME)

OTHER NAMES:

CN 1,3-Cyclohexanediol, 2-methylene-5-[(2E)-[(1R,3aS,7aR)-octahydro-1-[(1S)-5-hydroxy-1,5-dimethylhexyl]-7a-methyl-4H-inden-4-ylidene]ethylidene]-,  
(1R,3R)-

CN 2-Methylene-19-nor-20(S)-1 $\alpha$ ,25-dihydroxyvitamin D3

CN 2MD

FS STEREOSEARCH


MF C27 H44 O3

SR CA

LC STN Files: CA, CAPLUS, CASREACT, IMSDRUGNEWS, IMSRESEARCH, TOXCENTER,  
USPAT2, USPATFULL

Absolute stereochemistry.

Double bond geometry as shown.



\*\*PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT\*\*

48 REFERENCES IN FILE CA (1907 TO DATE)

10782337

QAZI

48 REFERENCES IN FILE CAPLUS (1907 TO DATE)

=> FILE CAPLUS	SINCE FILE	TOTAL
COST IN U.S. DOLLARS	ENTRY	SESSION
FULL ESTIMATED COST	8.10	8.31

FILE 'CAPLUS' ENTERED AT 13:33:54 ON 19 JAN 2007  
USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.  
PLEASE SEE "HELP USAGETERMS" FOR DETAILS.  
COPYRIGHT (C) 2007 AMERICAN CHEMICAL SOCIETY (ACS)

Copyright of the articles to which records in this database refer is held by the publishers listed in the PUBLISHER (PB) field (available for records published or updated in Chemical Abstracts after December 26, 1996), unless otherwise indicated in the original publications. The CA Lexicon is the copyrighted intellectual property of the American Chemical Society and is provided to assist you in searching databases on STN. Any dissemination, distribution, copying, or storing of this information, without the prior written consent of CAS, is strictly prohibited.

FILE COVERS 1907 - 19 Jan 2007 VOL 146 ISS 5  
FILE LAST UPDATED: 18 Jan 2007 (20070118/ED)

Effective October 17, 2005, revised CAS Information Use Policies apply. They are available for your review at:

<http://www.cas.org/infopolicy.html>

=> S L1 AND L2 AND L4  
1 L1  
29 L2  
48 L4  
L5 0 L1 AND L2 AND L4

=> 1 L1  
1 IS NOT A RECOGNIZED COMMAND  
The previous command name entered was not recognized by the system.  
For a list of commands available to you in the current file, enter "HELP COMMANDS" at an arrow prompt (=>).

=> S L1  
L6 1 L1

=> S L2  
L7 29 L2

=> S L4  
L8 48 L4

=> S L7 AND L8  
L9 27 L7 AND L8

=> S L1 OR L2 OR L4 AND CANCER  
1 L1

10782337

QAZI

29 L2  
48 L4  
303251 CANCER  
L10 34 L1 OR L2 OR L4 AND CANCER

=> D L10 1-34 IBIB HITSTR ABS

L10 ANSWER 1 OF 34 CAPLUS COPYRIGHT 2007 ACS on STN

ACCESSION NUMBER: 2005:283341 CAPLUS

DOCUMENT NUMBER: 142:310363

TITLE: Preparation of 2-alkylidene-19-nor-vitamin D derivatives for the treatment of hypocalcemic tetany or hypoparathyroidism

INVENTOR(S): Miller, Jeffrey Wells; Nduaka, Chudi Ike

PATENT ASSIGNEE(S): Pfizer Products Inc., USA

SOURCE: PCT Int. Appl., 45 pp.

CODEN: PIXXD2

DOCUMENT TYPE: Patent

LANGUAGE: English

FAMILY ACC. NUM. COUNT: 1

PATENT INFORMATION:


PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2005027928	A1	20050331	WO 2004-IB2910	20040906
W:	AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW			
RW:	BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG			
US 2005101578	A1	20050512	US 2004-943562	20040916
PRIORITY APPLN. INFO.:			US 2003-504022P	P 20030919
IT 213319-29-0P				
RL:	PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)			
	(preparation of 2-alkylidene-19-nor-vitamin D derivs. for treatment of hypocalcemic tetany or hypoparathyroidism)			
RN 213319-29-0 CAPLUS				
CN 19-Nor-9,10-secocholesta-5,7-diene-1,3,25-triol, 2-methylene-, (1 $\alpha$ ,3 $\beta$ ,7E)- (9CI) (CA INDEX NAME)				

Absolute stereochemistry.

Double bond geometry as shown.

10782337

QAZI



AB The present invention relates to methods of treating hypocalcemic tetany or hypoparathyroidism, the methods comprising administering to a patient in need thereof a 2-alkylidene-19-nor-vitamin D derivative. Particularly, the present invention relates to methods of treating hypocalcemic tetany or hypoparathyroidism, the methods comprising administering to a patient in need thereof a therapeutically effective amount of 2-methylene-19-nor-20(S)-1a,25-dihydroxyvitamin D3.

REFERENCE COUNT: 7 THERE ARE 7 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L10 ANSWER 2 OF 34 CAPLUS COPYRIGHT 2007 ACS on STN

ACCESSION NUMBER: 2005:283340 CAPLUS

DOCUMENT NUMBER: 142:341912

TITLE: Pharmaceutical compositions and methods comprising combinations of 2-alkylidene-19-nor-vitamin D derivatives and an estrogen agonist/antagonist

INVENTOR(S): Lee, Andrew George

PATENT ASSIGNEE(S): Pfizer Products Inc., USA

SOURCE: PCT Int. Appl., 71 pp.

CODEN: PIXXD2

DOCUMENT TYPE: Patent

LANGUAGE: English

FAMILY ACC. NUM. COUNT: 1

PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2005027924	A1	20050331	WO 2004-IB2900	20040906
W:	AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW			
RW:	BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG			
AU 2004273658	A1	20050331	AU 2004-273658	20040906
CA 2539361	A1	20050331	CA 2004-2539361	20040906
EP 1667692	A1	20060614	EP 2004-769299	20040906
R:	AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, FI, RO, CY, TR, BG, CZ, EE, HU, PL, SK			
CN 1852720	A	20061025	CN 2004-80026832	20040906


10782337

QAZI

BR 2004014448	A	20061114	BR 2004-14448	20040906
US 2005070512	A1	20050331	US 2004-943568	20040916
NO 2006001702	A	20060619	NO 2006-1702	20060418
PRIORITY APPLN. INFO.:			US 2003-504521P	P 20030919
			WO 2004-IB2900	W 20040906

IT 213319-29-0P  
RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)  
(pharmaceutical combinations of 2-alkylidene-19-nor-vitamin D derivs. and an estrogen agonist/antagonist)  
RN 213319-29-0 CAPLUS  
CN 19-Nor-9,10-secocholesta-5,7-diene-1,3,25-triol, 2-methylene-, (1 $\alpha$ ,3 $\beta$ ,7E)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.  
Double bond geometry as shown.



AB The present invention relates to pharmaceutical compns. and methods of treatment comprising administering to a patient in need thereof a combination of a 2-alkylidene-19-nor-vitamin D derivative and an estrogen agonist/antagonist or a pharmaceutically acceptable salt or prodrug thereof. Particularly, the present invention relates to pharmaceutical compns. and methods of treatment comprising administering to a patient in need thereof 2-methylene-19-nor-20(S)-Ia, 25-dihydroxyvitamin D<sub>3</sub> and (-)-cis-6-phenyl-5-[4-(2-pyrrolidin-1-yl-ethoxy)-phenyl]-5,6,7,8-tetrahydronaphthalene-2-ol, or a pharmaceutically acceptable salt or prodrug thereof.

REFERENCE COUNT: 6 THERE ARE 6 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L10 ANSWER 3 OF 34 CAPLUS COPYRIGHT 2007 ACS on STN

ACCESSION NUMBER: 2005:283339 CAPLUS

DOCUMENT NUMBER: 142:310362

TITLE: Preparation of 2-alkylidene-19-nor-vitamin D derivatives for the treatment of rickets or vitamin D deficiency

INVENTOR(S): Miller, Jeffrey Wells; Nduaka, Chudi Ike

PATENT ASSIGNEE(S): Pfizer Products Inc., USA

SOURCE: PCT Int. Appl., 42 pp.

CODEN: PIXXD2

DOCUMENT TYPE: Patent

LANGUAGE: English

FAMILY ACC. NUM. COUNT: 1

PATENT INFORMATION:


10782337



QAZI

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2005027920	A1	20050331	WO 2004-IB2925	20040906
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW				
RW: BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				
US 2005101577	A1	20050512	US 2004-942382	20040916
PRIORITY APPLN. INFO.:			US 2003-503811P	P 20030919
IT 213319-29-0P				
RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)				
(preparation of 2-alkylidene-19-nor-vitamin D derivs. for the treatment of rickets or vitamin D deficiency)				
RN 213319-29-0 CAPLUS				
CN 19-Nor-9,10-secocholesta-5,7-diene-1,3,25-triol, 2-methylene-, (1 $\alpha$ ,3 $\beta$ ,7E)- (9CI) (CA INDEX NAME)				

Absolute stereochemistry.  
Double bond geometry as shown.



AB The present invention relates to methods of treating vitamin D deficiency, particularly rickets, the methods comprising administering to a patient in need thereof a 2-alkylidene-19-nor-vitamin D derivative. Particularly, the present invention relates to methods of treating vitamin D deficiency with 2-methylene-19-nor-20(S)-1 $\alpha$ ,25-dihydroxyvitamin D<sub>3</sub>.

REFERENCE COUNT: 4 THERE ARE 4 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L10 ANSWER 4 OF 34 CAPLUS COPYRIGHT 2007 ACS on STN

ACCESSION NUMBER: 2005:259681 CAPLUS

DOCUMENT NUMBER: 142:317006

TITLE: Pharmaceutical compositions and methods comprising combinations of 2-alkylidene-19-nor-vitamin D derivatives and a growth hormone secretagogue

INVENTOR(S): Lee, Andrew G.

PATENT ASSIGNEE(S): Pfizer Inc, USA

SOURCE: U.S. Pat. Appl. Publ., 23 pp.

10782337

QAZI

CODEN: USXXCO  
DOCUMENT TYPE: Patent  
LANGUAGE: English  
FAMILY ACC. NUM. COUNT: 1  
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
US 2005065180	A1	20050324	US 2004-942376	20040916
WO 2005027913	A1	20050331	WO 2004-IB2899	20040906

W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW

RW: BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG

PRIORITY APPLN. INFO.: US 2003-504001P P 20030919

IT 213319-29-0P

RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)


(preparation 2-methylene-19-norvitamin D derivs. for use in compns. with a growth hormone secretagogue)

RN 213319-29-0 CAPLUS

CN 19-Nor-9,10-secocholesta-5,7-diene-1,3,25-triol, 2-methylene-, (1 $\alpha$ ,3 $\beta$ ,7E)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.


Double bond geometry as shown.



GI

10782337

OAZ I



AB The present invention relates to pharmaceutical compns. and methods of treatment comprising administering to a patient in need thereof a combination of a 2-alkylidene-19-nor-vitamin D derivative and a growth hormone secretagogue or a pharmaceutically acceptable salt or prodrug thereof. Particularly, the present invention relates to pharmaceutical compns. and methods of treatment comprising administering to a patient in need thereof 2-methylene-19-nor-20(S)-1 $\alpha$ ,25-dihydroxyvitamin D3 and a growth hormone secretagogue (e.g. I) or a pharmaceutically acceptable salt or prodrug thereof.

L10 ANSWER 5 OF 34 CAPLUS COPYRIGHT 2007 ACS on STN

ACCESSION NUMBER: 2005:259665 CAPLUS

DOCUMENT NUMBER: 142:310360

TITLE: Preparation of 2-alkylidene-19-nor-vitamin D derivatives for the treatment of anorexia or low bone mass in females exhibiting aggressive athletic behavior

INVENTOR(S): Thompson, David D.

PATENT ASSIGNEE(S): Pfizer Inc., USA

SOURCE: U.S. Pat. Appl. Publ., 16 pp.

CODEN: USXXCO

DOCUMENT TYPE: Patent

LANGUAGE: English

FAMILY ACC. NUM. COUNT: 1

PATENT INFORMATION:

PATENT NO.		KIND	DATE	APPLICATION NO.		DATE
US 2005065134		A1	20050324	US 2004-944368		20040916
WO 2005027925		A1	20050331	WO 2004-IB2904		20040906
W:	AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW					
RW:	BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG					

PRIORITY APPLN. INFO.: US 2003-504510P P 20030919

OTHER SOURCE(S): CASREACT 142:310360

IT 213319-29-0P

RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES

10782337

QAZ I

(Uses)


(preparation of 2-alkylidene-19-nor-vitamin D derivs. for treatment of anorexia or low bone mass in females exhibiting aggressive athletic behavior)

RN 213319-29-0 CAPLUS

19-Nor-9,10-secocholesta-5,7-diene-1,3,25-triol, 2-methylene-,  
(1 $\alpha$ ,3 $\beta$ ,7E)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.

Double bond geometry as shown.



AB The present invention relates to methods of treating anorexia or low bone mass in females exhibiting aggressive athletic behavior, the methods comprising administering to a patient in need thereof a 2-alkylidene-19-nor-vitamin D derivative. Particularly, the present invention relates to methods of treating anorexia or low bone mass in females exhibiting aggressive athletic behavior, the methods comprising administering to a patient in need thereof 2-methylene-19-nor-20(S)-1 $\alpha$ ,25-dihydroxy-vitamin D<sub>3</sub>.

L10 ANSWER 6 OF 34 CAPLUS COPYRIGHT 2007 ACS on STN

ACCESSION NUMBER: 2005:259664 CAPLUS

DOCUMENT NUMBER: 142:317005

Pharmaceutical compositions and methods comprising combinations of 2-alkylidene-19-nor-vitamin d derivatives and an ep2 or ep4 selective agonist

INVENTOR(S): Lee, Andrew G.; Thompson, David D.

PATENT ASSIGNEE(S): Pfizer Inc., USA

SOURCE: U.S. Pat. Appl. Publ., 49 pp.

CODEN: USXXCO

DOCUMENT TYPE: Patent

LANGUAGE: English

FAMILY ACC. NUM. COUNT: 1

PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
US 2005065133	A1	20050324	US 2004-944119	20040916
WO 2005027931	A1	20050331	WO 2004-IB2949	20040906
W:	AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW			
RW:	BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM,			

10782337

QAZI

AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK,  
EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PL, PT, RO, SE,  
SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE,  
SN, TD, TG

PRIORITY APPLN. INFO.:

US 2003-503798P

P 20030919

IT 213250-70-5P 213319-29-0P

RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU  
(Therapeutic use); BIOL (Biological study); PREP (Preparation); USES  
(Uses)


(pharmaceutical compns. and methods comprising combinations of  
2-alkylidene-19-nor-vitamin D derivs. and aromatase inhibitors)

RN 213250-70-5 CAPLUS

CN 19-Nor-9,10-secocholesta-5,7-diene-1,3,25-triol, 2-methylene-,  
(1 $\alpha$ ,3 $\beta$ ,7E,20S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.

Double bond geometry as shown.




RN 213319-29-0 CAPLUS

CN 19-Nor-9,10-secocholesta-5,7-diene-1,3,25-triol, 2-methylene-,  
(1 $\alpha$ ,3 $\beta$ ,7E)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.

Double bond geometry as shown.



AB The present invention relates to pharmaceutical compns. and methods of treatment comprising administering to a patient in need thereof a combination of a 2-alkylidene-19-nor-vitamin D derivative and an EP2 or EP4 selective agonist or a pharmaceutically acceptable salt or prodrug thereof. Particularly, the present invention relates to pharmaceutical compns. and methods comprising administering to a patient in need thereof 2-methylene-19-nor-20(S)-1 $\alpha$ ,25-dihydroxyvitamin D3 and an EP2 or EP4 selective agonist or a pharmaceutically acceptable salt or prodrug thereof.

10782337

QAZI

L10 ANSWER 7 OF 34 CAPLUS COPYRIGHT 2007 ACS on STN

ACCESSION NUMBER: 2005:259663 CAPLUS

DOCUMENT NUMBER: 142:310359

TITLE: Preparation of 2-alkylidene-19-nor-vitamin D derivatives for the treatment or prevention of a second hip fracture

INVENTOR(S): Thompson, David D.

PATENT ASSIGNEE(S): Pfizer Inc., USA

SOURCE: U.S. Pat. Appl. Publ., 16 pp.

CODEN: USXXCO

DOCUMENT TYPE: Patent

LANGUAGE: English

FAMILY ACC. NUM. COUNT: 1

PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
US 2005065132	A1	20050324	US 2004-944065	20040916
WO 2005027919	A1	20050331	WO 2004-IB2914	20040906
W:	AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW			
RW:	BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG			

PRIORITY APPLN. INFO.: US 2003-504004P P 20030919

OTHER SOURCE(S): CASREACT 142:310359

IT 213319-29-0P

RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)


(preparation of 2-alkylidene-19-nor-vitamin D derivs. for treatment or prevention of a second hip fracture)

RN 213319-29-0 CAPLUS

CN 19-Nor-9,10-secocholesta-5,7-diene-1,3,25-triol, 2-methylene-, (1 $\alpha$ ,3 $\beta$ ,7E)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.

Double bond geometry as shown.



10782337

QAZI

AB The present invention relates to methods of treating or preventing a second hip fracture, the methods comprising administering to a patient in need thereof a 2-alkylidene-19-nor-vitamin D derivative. Particularly, the present invention relates to methods of treating or preventing a second hip fracture, the methods comprising administering to a patient in need thereof a therapeutically effective amount of 2-methylene-19-nor-20(S)-1 $\alpha$ ,25-dihydroxyvitamin D 3.

L10 ANSWER 8 OF 34 CAPLUS COPYRIGHT 2007 ACS on STN

ACCESSION NUMBER: 2005:259662 CAPLUS

DOCUMENT NUMBER: 142:310358

TITLE: Preparation of 2-alkylidene-19-nor-vitamin D derivatives for enhancement of peak bone mass in adolescence

INVENTOR(S): Thompson, David D.

PATENT ASSIGNEE(S): Pfizer Inc., USA

SOURCE: U.S. Pat. Appl. Publ., 16 pp.

CODEN: USXXCO

DOCUMENT TYPE: Patent

LANGUAGE: English

FAMILY ACC. NUM. COUNT: 1

PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
US 2005065131	A1	20050324	US 2004-944063	20040916
WO 2005027927	A1	20050331	WO 2004-IB2906	20040906
W:	AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW			
RW:	BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG			

PRIORITY APPLN. INFO.: US 2003-504511P P 20030919

OTHER SOURCE(S): CASREACT 142:310358

IT 213319-29-0P

RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)

(preparation of 2-alkylidene-19-nor-vitamin D derivs. for enhancement of peak bone mass in adolescence)

RN 213319-29-0 CAPLUS


CN 19-Nor-9,10-secocholesta-5,7-diene-1,3,25-triol, 2-methylene-, (1 $\alpha$ ,3 $\beta$ ,7E)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.

Double bond geometry as shown.

10782337

QAZI



AB The present invention relates to methods of enhancing peak bone mass in adolescence, the methods comprising administering to a patient in need thereof a 2-alkylidene-19-nor-vitamin D derivative. Particularly, the present invention relates to methods of enhancing peak bone mass in adolescence, the methods comprising administering to a patient in need thereof a therapeutically effective amount of 2-methylene-19-nor-20(S)-1 $\alpha$ ,25-dihydroxyvitamin D<sub>3</sub>.

L10 ANSWER 9 OF 34 CAPLUS COPYRIGHT 2007 ACS on STN

ACCESSION NUMBER: 2005:259661 CAPLUS

DOCUMENT NUMBER: 142:336520

TITLE: Preparation, pharmaceutical compositions, and methods comprising combinations of 2-alkylidene-19-nor-vitamin D derivatives and a cyclooxygenase-2 inhibitor

INVENTOR(S): Thompson, David D.

PATENT ASSIGNEE(S): Pfizer Inc., USA

SOURCE: U.S. Pat. Appl. Publ., 20 pp.

CODEN: USXXCO

DOCUMENT TYPE: Patent

LANGUAGE: English

FAMILY ACC. NUM. COUNT: 1

PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
US 2005065130	A1	20050324	US 2004-943561	20040916
WO 2005027918	A1	20050331	WO 2004-IB2913	20040906
W:	AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW			
RW:	BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG			

PRIORITY APPLN. INFO.:

US 2003-504003P P 20030919

IT 213250-70-5P 213319-29-0P

RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)

(preparation of and pharmaceutical compns. and methods comprising combinations of 2-alkylidene-19-nor-vitamin D derivs. and aromatase

10782337



QAZI


inhibitors)

RN 213250-70-5 CAPLUS

CN 19-Nor-9,10-secocholesta-5,7-diene-1,3,25-triol, 2-methylene-,  
(1 $\alpha$ ,3 $\beta$ ,7E,20S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.

Double bond geometry as shown.




RN 213319-29-0 CAPLUS

CN 19-Nor-9,10-secocholesta-5,7-diene-1,3,25-triol, 2-methylene-,  
(1 $\alpha$ ,3 $\beta$ ,7E)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.

Double bond geometry as shown.



GI

10782337

AB The invention relates to pharmaceutical compns., and methods of treatment comprising administering to a patient in need of a combination of a 2-alkylidene-19-nor-vitamin D derivative and a cyclooxygenase-2 inhibitor, or a pharmaceutically acceptable salt or prodrug thereof. Particularly, the invention relates to pharmaceutical compns. and methods of treatment comprising administering to a patient in need of 2-methylene-19-nor-20(S)-10,25-dihydroxyvitamin D3 and a cyclooxygenase-2 inhibitor, or a pharmaceutically acceptable salt or prodrug thereof. Thus, 1 $\alpha$ ,25-dihydroxy-2-methylene-19-norvitamin D3 (I) was prepared in 11 steps from (-)-quinic acid, and (20S)-1 $\alpha$ ,25-dihydroxy-2-methylene-19-norvitamin D3 was prepared from (20S)-25-[(triethylsilyl)oxy]-des-A,B-cholestan-8-one in 4 steps.

ACCESSION NUMBER: 2005:259660 CAPLUS  
 DOCUMENT NUMBER: 142:310357  
 TITLE: Preparation of 2-alkylidene-19-nor-vitamin D  
 derivatives for the treatment of frailty, muscle  
 damage or sarcopenia  
 INVENTOR(S): Lee, Andrew G.  
 PATENT ASSIGNEE(S): Pfizer Inc., USA  
 SOURCE: U.S. Pat. Appl. Publ., 16 pp.  
 CODEN: USXXCO  
 DOCUMENT TYPE: Patent  
 LANGUAGE: English  
 FAMILY ACC. NUM. COUNT: 1  
 PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
US 2005065129	A1	20050324	US 2004-943553	20040916
AU 2004273659	A1	20050331	AU 2004-273659	20040906
CA 2538993	A1	20050331	CA 2004-2538993	20040906
WO 2005027914	A1	20050331	WO 2004-IB2901	20040906
W:	AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NI,			

QAZI

NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY,  
TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW  
RW: BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM,  
AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK,  
EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PL, PT, RO, SE,  
SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE,  
SN, TD, TG  
EP 1667688 A1 20060614 EP 2004-769300 20040906  
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT,  
IE, SI, FI, RO, CY, TR, BG, CZ, EE, HU, PL, SK  
CN 1852718 A 20061025 CN 2004-80027153 20040906  
BR 2004014564 A 20061107 BR 2004-14564 20040906  
NO 2006001704 A 20060619 NO 2006-1704 20060418  
PRIORITY APPLN. INFO.: US 2003-504509P P 20030919  
WO 2004-IB2901 W 20040906

IT 213319-29-0P


RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU  
(Therapeutic use); BIOL (Biological study); PREP (Preparation); USES  
(Uses)

(preparation of 2-alkylidene-19-nor-vitamin D derivs. for the treatment of  
frailty, muscle damage or sarcopenia)

RN 213319-29-0 CAPLUS

CN 19-Nor-9,10-secocholesta-5,7-diene-1,3,25-triol, 2-methylene-,  
(1 $\alpha$ ,3 $\beta$ ,7E)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.  
Double bond geometry as shown.



AB The present invention relates to methods of treating frailty, muscle  
damage or sarcopenia, the methods comprising administering to a patient in  
need thereof a 2-alkylidene-19-nor-vitamin D derivative. Particularly, the  
present invention relates to methods of treating frailty, muscle damage or  
sarcopenia, the methods comprising administering to a patient in need  
thereof a therapeutically effective amount of 2-methylene-19-nor-20(S)-  
1 $\alpha$ ,25-dihydroxyvitamin D<sub>3</sub>.

L10 ANSWER 11 OF 34 CAPLUS COPYRIGHT 2007 ACS on STN

ACCESSION NUMBER: 2005:259659 CAPLUS

DOCUMENT NUMBER: 142:310356

TITLE: Preparation of 2-alkylidene-19-nor-vitamin D  
derivatives for the treatment of hypogonadism or  
andropause

INVENTOR(S): Campagnari, Judith L.

PATENT ASSIGNEE(S): Pfizer Inc., USA

SOURCE: U.S. Pat. Appl. Publ., 16 pp.

CODEN: USXXCO

10782337

QAZI

DOCUMENT TYPE: Patent  
LANGUAGE: English  
FAMILY ACC. NUM. COUNT: 1  
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
US 2005065128	A1	20050324	US 2004-943059	20040916
WO 2005027922	A1	20050331	WO 2004-IB2937	20040906
W:	AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW			
RW:	BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG			

PRIORITY APPLN. INFO.: US 2003-503810P P 20030919

OTHER SOURCE(S): MARPAT 142:310356

IT 213319-29-0P

RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)


(preparation of 2-alkylidene-19-nor-vitamin D derivs. for treatment of hypogonadism or andropause)

RN 213319-29-0 CAPLUS

CN 19-Nor-9,10-secocholesta-5,7-diene-1,3,25-triol, 2-methylene-, (1 $\alpha$ ,3 $\beta$ ,7E)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.

Double bond geometry as shown.



AB The present invention relates to methods of treating hypogonadism or andropause, the methods comprising administering to a patient in need thereof a 2-alkylidene-19-nor-vitamin D derivative. Particularly, the present invention relates to methods of treating hypogonadism or andropause, the methods comprising administering to a patient in need thereof 2-methylene-19-nor-20(S)-1 $\alpha$ ,25-dihydroxyvitamin D 3.

L10 ANSWER 12 OF 34 CAPLUS COPYRIGHT 2007 ACS on STN

ACCESSION NUMBER: 2005:259658 CAPLUS

DOCUMENT NUMBER: 142:310355

TITLE: Preparation of 2-alkylidene-19-nor-vitamin D

10782337

QAZI

INVENTOR(S): derivatives for the treatment of osteosarcoma  
Campagnari, Judith L.  
PATENT ASSIGNEE(S): Pfizer Inc., USA  
SOURCE: U.S. Pat. Appl. Publ., 16 pp.  
CODEN: USXXCO  
DOCUMENT TYPE: Patent  
LANGUAGE: English  
FAMILY ACC. NUM. COUNT: 1  
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
US 2005065127	A1	20050324	US 2004-942704	20040916
WO 2005027930	A1	20050331	WO 2004-IB2918	20040906
W:	AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW			
RW:	BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG			

PRIORITY APPLN. INFO.: US 2003-504021P P 20030919

OTHER SOURCE(S): MARPAT 142:310355

IT 213319-29-0P

RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)


(preparation of 2-alkylidene-19-nor-vitamin D derivs. for treatment of osteosarcoma)

RN 213319-29-0 CAPLUS

CN 19-Nor-9,10-secocholesta-5,7-diene-1,3,25-triol, 2-methylene-, (1 $\alpha$ ,3 $\beta$ ,7E)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.

Double bond geometry as shown.



AB The present invention relates to methods of treating osteosarcoma, the methods comprising administering to a patient in need thereof a 2-alkylidene-19-nor-vitamin D derivative. Particularly, the present invention relates to methods of treating osteosarcoma, the methods comprising administering to a patient in need thereof a therapeutically effective amount of 2-methylene-19-nor-20(S)-1 $\alpha$ ,25-dihydroxyvitamin D 3.

10782337

QAZI

L10 ANSWER 13 OF 34 CAPLUS COPYRIGHT 2007 ACS on STN

ACCESSION NUMBER: 2005:259657 CAPLUS

DOCUMENT NUMBER: 142:317004

TITLE: Pharmaceutical compositions and methods comprising combinations of 2-alkylidene-19-nor-vitamin D derivatives and aromatase inhibitors

INVENTOR(S): Lee, Andrew G.

PATENT ASSIGNEE(S): USA

SOURCE: U.S. Pat. Appl. Publ., 19 pp.

CODEN: USXXCO

DOCUMENT TYPE: Patent

LANGUAGE: English

FAMILY ACC. NUM. COUNT: 1

PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
US 2005065126	A1	20050324	US 2004-942613	20040916
WO 2005027916	A1	20050331	WO 2004-IB2903	20040906
W:	AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW			
RW:	BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG			

PRIORITY APPLN. INFO.:

US 2003-504005P P 20030919

IT 213250-70-5P 213319-29-0P

RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)


(pharmaceutical compns. and methods comprising combinations of 2-alkylidene-19-nor-vitamin D derivs. and aromatase inhibitors)

RN 213250-70-5 CAPLUS

CN 19-Nor-9,10-secocholesta-5,7-diene-1,3,25-triol, 2-methylene-, (1 $\alpha$ ,3 $\beta$ ,7E,20S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.

Double bond geometry as shown.



RN 213319-29-0 CAPLUS

10782337

CN 19-Nor-9,10-secocholesta-5,7-diene-1,3,25-triol, 2-methylene-,  
(1 $\alpha$ ,3 $\beta$ ,7E)- (9CI) (CA INDEX NAME)

Chemical structure of a complex steroid derivative, showing a steroid nucleus with a vinyl group at C17, a hydroxyl group at C13, and a methyl group at C10. The side chain at C13 is a 2-methyl-2-(3-hydroxy-3-methylbutyl)propyl group. Stereochemistry is indicated with wedges and dashes.

L10 ANSWER 14 OF 34 CAPLUS COPYRIGHT 2007 ACS on STN  
ACCESSION NUMBER: 2005:259656 CAPLUS  
DOCUMENT NUMBER: 142:310354  
TITLE: Preparation of 2-alkylidene-19-nor-vitamin D  
derivatives for the treatment of osteopenia or male  
osteoporosis  
INVENTOR(S): Campagnari, Judith L.; Lee, Andrew G.  
PATENT ASSIGNEE(S): Pfizer Inc., USA  
SOURCE: U.S. Pat. Appl. Publ., 16 pp.  
CODEN: USXXCO  
DOCUMENT TYPE: Patent  
LANGUAGE: English  
FAMILY ACC. NUM. COUNT: 1  
PATENT INFORMATION:

107.82337

QAZI

EP 1667690	A1	20060614	EP 2004-769311	20040906
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, FI, RO, CY, TR, BG, CZ, EE, HU, PL, SK				
CN 1852717	A	20061025	CN 2004-80026946	20040906
BR 2004014465	A	20061114	BR 2004-14465	20040906
NO 2006000655	A	20060616	NO 2006-655	20060209
PRIORITY APPLN. INFO.:			US 2003-504508P	P 20030919
			WO 2004-IB2912	W 20040906

OTHER SOURCE(S): MARPAT 142:310354

IT 213319-29-0P

RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU  
(Therapeutic use); BIOL (Biological study); PREP (Preparation); USES  
(Uses)


(preparation of 2-alkylidene-19-nor-vitamin D derivs. for treatment of  
osteopenia or male osteoporosis)

RN 213319-29-0 CAPLUS

CN 19-Nor-9,10-secocholesta-5,7-diene-1,3,25-triol, 2-methylene-,  
(1 $\alpha$ ,3 $\beta$ ,7E)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.

Double bond geometry as shown.



AB The present invention relates to methods of treating osteopenia or male osteoporosis, the methods comprising administering to a patient in need thereof a 2-alkylidene-19-nor-vitamin D derivative. Particularly, the present invention relates to methods of treating osteopenia or male osteoporosis, the methods comprising administering to a patient in need thereof 2-methylene-19-nor-20(S)-1 $\alpha$ ,25-dihydroxyvitamin D 3.

L10 ANSWER 15 OF 34 CAPLUS COPYRIGHT 2007 ACS on STN

ACCESSION NUMBER: 2005:259654 CAPLUS

DOCUMENT NUMBER: 142:291906

TITLE: Use of 2-methylene-19-nor-20(s)-1 $\alpha$ ,25-dihydroxyvitamin D3 to increase the life expectancy of human beings

INVENTOR(S): DeLuca, Hector F.; Plum, Lori A.; Clagette-Dame, Margaret

PATENT ASSIGNEE(S): USA

SOURCE: U.S. Pat. Appl. Publ., 5 pp.

CODEN: USXXCO

DOCUMENT TYPE: Patent

LANGUAGE: English

FAMILY ACC. NUM. COUNT: 1

PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
------------	------	------	-----------------	------

10782337



US 2005065123	A1	20050324	US 2003-669990	20030924
AU 2004280176	A1	20050421	AU 2004-280176	20040728
CA 2540051	A1	20050421	CA 2004-2540051	20040728
WO 2005034959	A1	20050421	WO 2004-US24482	20040728

W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW

RW: BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG

EP 1663251	A1	20060607	EP 2004-757375	20040728
------------	----	----------	----------------	----------

R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, FI, RO, CY, TR, BG, CZ, EE, HU, PL, SK

US 2006241090	A1	20061026	US 2006-472125	20060621
---------------	----	----------	----------------	----------


PRIORITY APPLN. INFO.: US 2003-669990 A 20030924  
WO 2004-US24482 W 20040728

IT 213250-70-5, 2-Methylene-19-nor-20(S)-1 $\alpha$ ,25-dihydroxyvitamin D3  
RL: PAC (Pharmacological activity); THU (Therapeutic use); BIOL (Biological study); USES (Uses)  
(method for increasing the life expectancy of human beings)

RN 213250-70-5 CAPLUS

CN 19-Nor-9,10-secocholesta-5,7-diene-1,3,25-triol, 2-methylene-, (1 $\alpha$ ,3 $\beta$ ,7E,20S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.  
Double bond geometry as shown.



AB The invention provides pharmaceutical uses for 2-methylene-19-nor-20(S)-1 $\alpha$ ,25-dihydroxyvitamin D3. Administration of this compound increases the life expectancy of human beings, especially elderly human beings. In particular, it increases the survival rate of females lacking estrogen, especially post-menopausal females, and reduces mortality resulting from spontaneous development of malignant tumors in both males and females.

L10 ANSWER 16 OF 34 CAPLUS COPYRIGHT 2007 ACS on STN

ACCESSION NUMBER: 2005:259653 CAPLUS

DOCUMENT NUMBER: 142:317003

TITLE: Pharmaceutical compositions and methods comprising combinations of 2-alkylidene-19-nor-vitamin D

QAZI


INVENTOR(S): derivatives and a bisphosphonate  
Lee, Andrew G.  
PATENT ASSIGNEE(S): Pfizer Inc, USA  
SOURCE: U.S. Pat. Appl. Publ., 20 pp.  
CODEN: USXXCO  
DOCUMENT TYPE: Patent  
LANGUAGE: English  
FAMILY ACC. NUM. COUNT: 1  
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
US 2005065117	A1	20050324	US 2004-942426	20040916
AU 2004273672	A1	20050331	AU 2004-273672	20040906
CA 2539359	A1	20050331	CA 2004-2539359	20040906
WO 2005027921	A1	20050331	WO 2004-IB2935	20040906
W:	AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW			
RW:	BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG			
EP 1667691	A1	20060614	EP 2004-769333	20040906
R:	AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, FI, RO, CY, TR, BG, CZ, EE, HU, PL, SK			
CN 1852719	A	20061025	CN 2004-80027165	20040906
BR 2004014565	A	20061107	BR 2004-14565	20040906
NO 2006001245	A	20060531	NO 2006-1245	20060317
PRIORITY APPLN. INFO.:	US 2003-504008P P 20030919 WO 2004-IB2935 W 20040906			
IT 213250-70-5P 213319-29-0P	RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses) (pharmaceutical compns. and methods comprising combinations of 2-alkylidene-19-nor-vitamin D derivs. and aromatase inhibitors)			
RN 213250-70-5 CAPLUS				
CN 19-Nor-9,10-secocholesta-5,7-diene-1,3,25-triol, 2-methylene-, (1 $\alpha$ ,3 $\beta$ ,7E,20S)- (9CI) (CA INDEX NAME)				

Absolute stereochemistry.  
Double bond geometry as shown.

10782337


QAZI



RN 213319-29-0 CAPLUS

CN 19-Nor-9,10-secosteroid-5,7-diene-1,3,25-triol, 2-methylene-,  
(1α,3β,7E)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.  
Double bond geometry as shown.



AB The present invention relates to pharmaceutical compns. and methods of treatment comprising administering to a patient in need thereof a combination of a 2-alkylidene-19-nor-vitamin D derivative and a bisphosphonate. Particularly, the present invention relates to pharmaceutical compns. and methods of treatment comprising administering to a patient in need thereof 2-methylene-19-nor-20(S)-1α,25-dihydroxyvitamin D3 and a bisphosphonate.

L10 ANSWER 17 OF 34 CAPLUS COPYRIGHT 2007 ACS on STN

ACCESSION NUMBER: 2005:259643 CAPLUS

DOCUMENT NUMBER: 142:317002

TITLE: Pharmaceutical compositions and methods comprising combinations of 2-alkylidene-19-nor-vitamin d derivatives and parathyroid hormone

INVENTOR(S): Thompson, David D.

PATENT ASSIGNEE(S): Pfizer Inc., USA

SOURCE: U.S. Pat. Appl. Publ., 19 pp.

CODEN: USXXCO

DOCUMENT TYPE: Patent

LANGUAGE: English

FAMILY ACC. NUM. COUNT: 1

PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
US 2005065088	A1	20050324	US 2004-946585	20040916

10782337

QAZI

AU 2004273660	A1	20050331	AU 2004-273660	20040906
CA 2539357	A1	20050331	CA 2004-2539357	20040906
WO 2005027915	A1	20050331	WO 2004-IB2902	20040906
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW				
RW: BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				
EP 1667689	A1	20060614	EP 2004-769301	20040906
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, FI, RO, CY, TR, BG, CZ, EE, HU, PL, SK				
CN 1852716	A	20061025	CN 2004-80026848	20040906
BR 2004014518	A	20061107	BR 2004-14518	20040906
NO 2006001236	A	20060615	NO 2006-1236	20060317
PRIORITY APPLN. INFO.:			US 2003-504503P	P 20030919
			WO 2004-IB2902	W 20040906

OTHER SOURCE(S): CASREACT 142:317002

IT 213250-70-5P 213319-29-0P

RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)


(pharmaceutical compns. and methods comprising combinations of 2-alkylidene-19-nor-vitamin D' derivs. and parathyroid hormone)

RN 213250-70-5 CAPLUS

CN 19-Nor-9,10-secocholesta-5,7-diene-1,3,25-triol, 2-methylene-, (1 $\alpha$ ,3 $\beta$ ,7E,20S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.

Double bond geometry as shown.



RN 213319-29-0 CAPLUS


CN 19-Nor-9,10-secocholesta-5,7-diene-1,3,25-triol, 2-methylene-, (1 $\alpha$ ,3 $\beta$ ,7E)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.

Double bond geometry as shown.

10782337

QAZI



AB The present invention relates to pharmaceutical compns. and methods of treatment comprising administering to a patient in need thereof a combination of a 2-alkylidene-19-nor-vitamin D derivative and parathyroid hormone or an active fragment or variant thereof. Particularly, the present invention relates to pharmaceutical compns. and methods of treatment comprising administering to a patient in need thereof 2-methylene-19-nor-20(S)-1 $\alpha$ ,25-dihydroxyvitamin D3 and parathyroid hormone or an active fragment or variant thereof.

L10 ANSWER 18 OF 34 CAPLUS COPYRIGHT 2007 ACS on STN

ACCESSION NUMBER: 2005:259642 CAPLUS

DOCUMENT NUMBER: 142:317001

TITLE: Pharmaceutical compositions and methods comprising combinations of 2-alkylidene-19-nor-vitamin D derivatives and a bone morphogenetic protein

INVENTOR(S): Campagnari, Judith L.

PATENT ASSIGNEE(S): Pfizer Inc., USA

SOURCE: U.S. Pat. Appl. Publ., 18 pp.

CODEN: USXXCO

DOCUMENT TYPE: Patent

LANGUAGE: English

FAMILY ACC. NUM. COUNT: 1

PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
US 2005065087	A1	20050324	US 2004-942725	20040916
WO 2005027926	A1	20050331	WO 2004-IB2905	20040906
W:	AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW			
RW:	BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG			

PRIORITY APPLN. INFO.:

US 2003-504161P P 20030919

IT 213250-70-5P 213319-29-0P

RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)


(pharmaceutical compns. and methods comprising combinations of

10782337

QAZI


2-alkylidene-19-nor-vitamin D derivs. and bone morphogenetic protein)  
RN 213250-70-5 CAPLUS  
CN 19-Nor-9,10-secocholesta-5,7-diene-1,3,25-triol, 2-methylene-,  
(1 $\alpha$ ,3 $\beta$ ,7E,20S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.  
Double bond geometry as shown.



RN 213319-29-0 CAPLUS  
CN 19-Nor-9,10-secocholesta-5,7-diene-1,3,25-triol, 2-methylene-,  
(1 $\alpha$ ,3 $\beta$ ,7E)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.  
Double bond geometry as shown.



AB The present invention relates to pharmaceutical compns. and methods of treatment comprising administering to a patient in need thereof a combination of a 2-alkylidene-19-nor-vitamin D derivs. and a bone morphogenetic protein or active fragment or variant thereof. Particularly, the present invention relates to pharmaceutical compns. and methods of treatment comprising administering to a patient in need thereof 2-methylene-19-nor-20(S)-1 $\alpha$ ,25-dihydroxyvitamin D 3 and a bone morphogenetic protein or active fragment or variant thereof.

L10 ANSWER 19 OF 34 CAPLUS COPYRIGHT 2007 ACS on STN

ACCESSION NUMBER: 2005:259356 CAPLUS

DOCUMENT NUMBER: 142:322752

TITLE: Pharmaceutical compositions and methods comprising combinations of 2-alkylidene-19-nor-vitamin D derivatives and an estrogen

INVENTOR(S): Keys, Sharon C.

PATENT ASSIGNEE(S): Pfizer Inc., USA

SOURCE: U.S. Pat. Appl. Publ., 19 pp.

CODEN: USXXCO

10782337


QAZI

DOCUMENT TYPE: Patent  
LANGUAGE: English  
FAMILY ACC. NUM. COUNT: 1  
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
US 2005063992	A1	20050324	US 2004-942384	20040916
WO 2005027929	A1	20050331	WO 2004-IB2911	20040906
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW				
RW: BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				

PRIORITY APPLN. INFO.: US 2003-504023P P 20030919  
IT 213250-70-5P 213319-29-0P  
RL: SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)  
(comps. comprising alkylidene vitamin D derivs. in combination with estrogen for treatment of bone disease, cancer and other diseases)  
RN 213250-70-5 CAPLUS  
CN 19-Nor-9,10-secocholesta-5,7-diene-1,3,25-triol, 2-methylene-, (1 $\alpha$ ,3 $\beta$ ,7E,20S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.  
Double bond geometry as shown.




RN 213319-29-0 CAPLUS  
CN 19-Nor-9,10-secocholesta-5,7-diene-1,3,25-triol, 2-methylene-, (1 $\alpha$ ,3 $\beta$ ,7E)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.  
Double bond geometry as shown.

10782337

QAZI



AB The present invention relates to pharmaceutical compns. and methods of treatment comprising administering to a patient in need thereof a combination of a 2-alkylidene-19-nor-vitamin D derivative and an estrogen, or a pharmaceutically acceptable salt or prodrug thereof. Particularly, the present invention relates to pharmaceutical compns. and methods of treatment, e.g. osteoporosis, bone fracture, breast cancer, prostate cancer, obesity, osteopenia; etc., comprising administering to a patient in need thereof 2-methylene-19-nor-20(S)-1 $\alpha$ ,25-dihydroxyvitamin D<sub>3</sub> (I) and an estrogen, or a pharmaceutically acceptable salt or prodrug thereof. For example, I was prepared and tested for biol. activity. I bound well to the porcine intestinal vitamin D receptor. When given at 130 pmol/day, its activity on bone calcium mobilization (serum calcium) was of the order of at least 10 and possible 100 to 1000 times more than that of the native hormone. Also, I was extremely potent in inducing differentiation of HL-60 cells to monocyte, illustrating its potential as anticancer agent.

L10 ANSWER 20 OF 34 CAPLUS COPYRIGHT 2007 ACS on STN

ACCESSION NUMBER: 2004:522177 CAPLUS

DOCUMENT NUMBER: 141:185224

TITLE: Model of three-dimensional structure of VDR bound with Vitamin D3 analogs substituted at carbon-2

AUTHOR(S): Sicinska, Wanda; Rotkiewicz, Piotr; DeLuca, Hector F.

CORPORATE SOURCE: Department of Biochemistry, University of Wisconsin-Madison, Madison, WI, 53706, USA

SOURCE: Journal of Steroid Biochemistry and Molecular Biology (2004), 89-90(1-5), 107-110  
CODEN: JSBBEZ; ISSN: 0960-0760

PUBLISHER: : Elsevier Science Ltd.

DOCUMENT TYPE: Journal

LANGUAGE: English

IT 213319-29-0

RL: BSU (Biological study, unclassified); PRP (Properties); BIOL (Biological study)

(model of three-dimensional structure of VDR bound with Vitamin D3 analogs substituted at carbon-2)

RN 213319-29-0 CAPLUS

CN 19-Nor-9,10-secocholesta-5,7-diene-1,3,25-triol, 2-methylene-, (1 $\alpha$ ,3 $\beta$ ,7E)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.

Double bond geometry as shown.

10782337



QAZI



AB All Vitamin D analogs possessing the A ring modified at C-2 and showing calcemic activities nest themselves in the VDR binding pocket, oriented towards Tyr 143. Such topol. resembles the position of the Vitamin D hormone in hVDRmt [Proc. Natl. Acad. Sci. U.S.A. 98 (2001) 5491]. Conversely, inactive 2 $\beta$ -methyl-19-nor-analogs anchor the receptor cavity in a distinguishably different manner, namely by their side chain. Moreover, these inactive vitamins have a different conformation around C(6)-C(7) bond. Topol. of modeled complexes suggests that a Vitamin D analog will be biol. active if its intercyyclic 5,7-diene moiety assumes parallel position to tryptophan aromatic rings; such orientation allows for creating  $\pi$ - $\pi$  interactions. The broad comparison of calcemic activities of the analogs, and their interactions with VDR, revealed that specific hydrophobic contacts are involved in bone calcium mobilization (BCM). These contacts occur between 21-Me group and a few amino acids (V296, L305 and L309), conserved in the nuclear receptor superfamily. In the inactive 2 $\beta$ -methyl-19-nor analogs such contacts do not exist. We speculate that two hydrophobic receptor patches, being in close contact with ligand Me groups, might influence interaction with co-modulators involved in calcium homeostasis.

REFERENCE COUNT: 12 THERE ARE 12 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L10 ANSWER 21 OF 34 CAPLUS COPYRIGHT 2007 ACS on STN

ACCESSION NUMBER: 2004:522171 CAPLUS

DOCUMENT NUMBER: 141:185221

TITLE: Therapeutic potential of the 2-alkyl and 2-alkylidene-19-nor-(20S)-modified analogs of 1 $\alpha$ ,25-dihydroxyvitamin D3

AUTHOR(S): DeLuca, Hector F.

CORPORATE SOURCE: Department of Biochemistry, University of Wisconsin-Madison, Madison, WI, 53706-1544, USA

SOURCE: Journal of Steroid Biochemistry and Molecular Biology (2004), 89-90(1-5), 67-73  
CODEN: JSBBEZ; ISSN: 0960-0760

PUBLISHER: : Elsevier Science Ltd.

DOCUMENT TYPE: Journal

LANGUAGE: English

IT 213250-70-5

RL: BSU (Biological study, unclassified); PAC (Pharmacological activity); THU (Therapeutic use); BIOL (Biological study); USES (Uses)  
(effects of 2-alkyl and 2-alkylidene-19-nor-(20S)-modified analogs of 1 $\alpha$ ,25-(OH)2D3 on PTH activity/bone mineral mobilization, and their therapeutic potential for diseases where a rise in serum calcium is not desired).


RN 213250-70-5 CAPLUS

10782337

QAZI

CN 19-Nor-9,10-secocholesta-5,7-diene-1,3,25-triol, 2-methylene-,  
(1 $\alpha$ ,3 $\beta$ ,7E,20S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.  
Double bond geometry as shown.



AB Five analogs of 19-nor-1 $\alpha$ ,25-dihydroxyvitamin D3 are described that show highly selective and potent activities. The 2-methylene-19-nor-(20S)-1 $\alpha$ ,25-dihydroxyvitamin D3 (2MD) and its 2 $\alpha$ -Me sister are selectively active on the osteoblast. 2MD is bone anabolic and causes bone formation in vivo and in vitro and is being developed as a therapy for bone loss diseases such as osteoporosis. 2-Methylene-19-nor-(20S)-bishomo-1 $\alpha$ -hydroxypregnacalciferol (2BMP) has no activity on calcium in vivo while totally suppressing circulating parathyroid hormone. Its homologs, i.e. 2-methylene-19-nor-1 $\alpha$ -hydroxy-homopregnacalciferol (2MP) and 2-methylene-19-nor-1 $\alpha$ -hydroxypregnacalciferol (2MPC) act similarly but are either less selective (2MP) or not as potent (2MPC). These abbreviated side chain analogs will be developed for diseases where a rise in serum calcium is not desired, as for example, cancer, renal osteodystrophy, psoriasis and autoimmune diseases.

REFERENCE COUNT: 21 THERE ARE 21 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L10 ANSWER 22 OF 34 CAPLUS COPYRIGHT 2007 ACS on STN

ACCESSION NUMBER: 2004:220021 CAPLUS

DOCUMENT NUMBER: 140:247113

TITLE: Method of extending the dose range of vitamin D compounds

INVENTOR(S): Deluca, Hector F.; Pike, John W.; Shevde, Nirupama; Plum, Lori A.; Clagett-Dame, Margaret

PATENT ASSIGNEE(S): USA

SOURCE: U.S. Pat. Appl. Publ., 17 pp.

CODEN: USXXCO

DOCUMENT TYPE: Patent

LANGUAGE: English

FAMILY ACC. NUM. COUNT: 1

PATENT INFORMATION:


PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
US 2004053813	A1	20040318	US 2002-235244	20020905
CA 2497828	A1	20040318	CA 2003-2497828	20030626
WO 2004022068	A1	20040318	WO 2003-US20517	20030626

W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH,

10782337

	GM,	HR,	HU,	ID,	IL,	IN,	IS,	JP,	KE,	KG,	KP,	KR,	KZ,	LC,	LK,	LR,	
	LS,	LT,	LU,	LV,	MA,	MD,	MG,	MK,	MN,	MW,	MX,	MZ,	NO,	NZ,	OM,	PH,	
	PL,	PT,	RO,	RU,	SC,	SD,	SE,	SG,	SK,	SL,	TJ,	TM,	TN,	TR,	TT,	TZ,	
	UA,	UG,	UZ,	VC,	VN,	YU,	ZA,	ZM,	ZW								
RW:	GH,	GM,	KE,	LS,	MW,	MZ,	SD,	SL,	SZ,	TZ,	UG,	ZM,	ZW,	AM,	AZ,	BY,	
	KG,	KZ,	MD,	RU,	TJ,	TM,	AT,	BE,	BG,	CH,	CY,	CZ,	DE,	DK,	EE,	ES,	
	FI,	FR,	GB,	GR,	HU,	IE,	IT,	LU,	MC,	NL,	PT,	RO,	SE,	SI,	SK,	TR,	
	BF,	BJ,	CF,	CG,	CI,	CM,	GA,	GN,	GQ,	GW,	ML,	MR,	NE,	SN,	TD,	TG	
AU	2003245748			A1		20040329			AU	2003-245748					20030626		
EP	1545549			A1		20050629			EP	2003-739354					20030626		
	R:	AT,	BE,	CH,	DE,	DK,	ES,	FR,	GB,	GR,	IT,	LI,	LU,	NL,	SE,	MC,	PT,
		IE,	SI,	LT,	LV,	FI,	RO,	MK,	CY,	AL,	TR,	BG,	CZ,	EE,	HU,	SK	
BR	2003014006			A		20050809			BR	2003-14006					20030626		
CN	1694711			A		20051109			CN	2003-824888					20030626		
JP	2006500388			T		20060105			JP	2004-534233					20030626		
PRIORITY APPLN. INFO.:									US	2002-235244				A	20020905		
									WO	2003-US20517				W	20030626		

Absolute stereochemistry.  
Double bond geometry as shown.




L10 ANSWER 23 OF 34 CAPLUS COPYRIGHT 2007 ACS on STN  
ACCESSION NUMBER: 2003:647469 CAPLUS

10782337

QAZI

DOCUMENT NUMBER: 139:271426  
TITLE: 2-Methylene-19-nor-(20S)-1,25-dihydroxyvitamin D3  
potently stimulates gene-specific DNA binding of  
vitamin D receptor in osteoblasts  
AUTHOR(S): Yamamoto, Hironori; Shevde, Nirupama K.; Warri-  
er, Anjali; Plum, Lori A.; DeLuca, Hector F.; Pike, J.  
Wesley  
CORPORATE SOURCE: Department of Biochemistry, University of  
Wisconsin-Madison, Madison, WI, 53706, USA  
SOURCE: Journal of Biological Chemistry (2003), 278(34),  
31756-31765  
CODEN: JBCHA3; ISSN: 0021-9258  
PUBLISHER: American Society for Biochemistry and Molecular  
Biology  
DOCUMENT TYPE: Journal  
LANGUAGE: English  
IT 213319-29-0  
RL: BSU (Biological study, unclassified); BIOL (Biological study)  
(2-methylene-19-nor-(20S)-1,25-dihydroxyvitamin D3 potently stimulates  
gene-specific DNA binding of vitamin D receptor in osteoblasts in  
relation to underlying mol. mechanism)  
RN 213319-29-0 CAPLUS  
CN 19-Nor-9,10-secocholesta-5,7-diene-1,3,25-triol, 2-methylene-,  
(1 $\alpha$ ,3 $\beta$ ,7E)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.  
Double bond geometry as shown.



AB 2-Methylene-19-nor-(20S)-1,25-dihydroxyvitamin D3 (2MD) is a highly potent analog of 1,25-dihydroxyvitamin D3 (1,25(OH)2D3) whose actions are mediated through the vitamin D receptor (VDR). The authors have replicated this increased potency of 2MD in vitro using osteoblastic cells and explored its underlying mol. mechanism. 2MD stimulates the expression of several vitamin D-sensitive genes including 25-hydroxyvitamin D3-24 hydroxylase (Cyp24), osteopontin and receptor activator of NF $\kappa$ B ligand and suppresses osteoprotegerin at concns. two logs lower than that for 1,25(OH)2D3. 2MD is also more potent in stimulating transfected chimeric reporter genes under either Cyp24 or the osteocalcin promoter control. Enhanced potency is retained regardless of medium serum content. Interestingly, the uptake of both 1,25(OH)2D3 and 2MD into cells is similar, as is their rapid association with the VDR. This indicates that comparable levels of occupied VDR do not elicit equivalent levels of transactivation. Using chromatin immunoprecipitation (ChIP), however, the authors observed a strong correlation between DNA-bound receptor and the level of induced transcription suggesting a 2MD-induced increase in affinity of the VDR for DNA. Addnl. studies using a mammalian two-hybrid system and ChIP

10782337

QAZI

indicate that 2MD is also more potent in promoting interaction with RXR and the coactivators SRC-1 and DRIP205. Finally, protease digestion studies revealed a unique VDR conformation in the presence of 2MD. These studies suggest that the mol. mechanism of 2MD potency is due to its ability to promote enhanced levels of specific DNA binding by the VDR and could suggest possible explanations for the tissue- and gene-selective actions of 2MD.

REFERENCE COUNT: 52 THERE ARE 52 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L10 ANSWER 24 OF 34 CAPLUS COPYRIGHT 2007 ACS on STN

ACCESSION NUMBER: 2002:387626 CAPLUS

DOCUMENT NUMBER: 136:401925

TITLE: Preparation of 26,27-homologated-20-epi-2-alkylidene-19-nor-vitamin D compounds as antiosteoporotics and antitumor agents

INVENTOR(S): Deluca, Hector F.; Sicinski, Rafal R.

PATENT ASSIGNEE(S): Wisconsin Alumni Research Foundation, USA

SOURCE: U.S., 22 pp., Cont.-in-part of U.S. Ser. No. 370,966, abandoned.

CODEN: USXXAM

DOCUMENT TYPE: Patent

LANGUAGE: English

FAMILY ACC. NUM. COUNT: 3

PATENT INFORMATION:


PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
US 6392071	B1	20020521	US 2000-540686	20000331
US 5843928	A	19981201	US 1997-819693	19970317
US 5936133	A	19990810	US 1998-151113	19980910
CA 2404548	A1	20011011	CA 2001-2404548	20010329
WO 2001074766	A1	20011011	WO 2001-US10317	20010329
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CR, CU, CZ, DE, DK, DM, DZ, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, UZ, VN, YU, ZA, ZW				
RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG				
EP 1268416	A1	20030102	EP 2001-920897	20010329
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR				
JP 2003529581	T	20031007	JP 2001-572461	20010329
NZ 522160	A	20041126	NZ 2001-522160	20010329
US 2002087015	A1	20020704	US 2001-1711	20011031
US 6537981	B2	20030325		
US 2003181427	A1	20030925	US 2003-352745	20030128
US 6696431	B2	20040224		
US 2004167104	A1	20040826	US 2004-780103	20040217
US 7094774	B2	20060822		
JP 2006117680	A	20060511	JP 2005-319365	20051102
PRIORITY APPLN. INFO.:				US 1997-819693 A3 19970317
				US 1998-151113 A1 19980910
				US 1999-370966 B2 19990810
				JP 1998-540501 A3 19980211

10782337

QAZI


OTHER SOURCE(S): M  
IT 213250-70-5P 213319-2  
RL: PAC (Pharmacologi  
(Therapeutic use); BI  
(Uses)  
(preparation of 26  
comps. as antiost  
RN 213250-70-5 CAPLUS  
CN 19-Nor-9,10-secochole  
(1 $\alpha$ ,3 $\beta$ ,7E,20S)- (9CI)

Absolute stereochemistry.  
Double bond geometry as sh



RN 213319-29-0 CAPLUS  
CN 19-Nor-9,10-secochole  
(1 $\alpha$ ,3 $\beta$ ,7E)- (9CI) (C)

Absolute stereochemistry.  
Double bond geometry as sh



GI

\* STRUCTURE DIAGRAM TOO LA

AB Novel vitamin D relat  
derivs. of formula I


10782337

cal activity); SYN (Synthetic preparation); THE  
OL (Biological study); PREP (Preparation); USES

,27-homologated-20-epi-2-alkylidene-19-nor-vitamin D  
eoporotics and antitumor agents)


sta-5,7-diene-1,3,25-triol, 2-methylene-,  
(CA INDEX NAME)

own.



sta-5,7-diene-1,3,25-triol, 2-methylene-,  
(A INDEX NAME)

own.



RGE FOR DISPLAY - AVAILABLE VIA OFFLINE PRINT \*

ed compds., namely, 2-alkylidene-19-nor-vitamin D  
[Y1, Y2 = H, protecting group; R6, R8 = alkyl,

US 2000-540686	A 20000331
WO 2001-US10317	W 20010329
US 2001-1711	A3 20011031
US 2003-352745	A3 20030128

ARPAT 136:401925

9-OP

cal activity); SYN (Synthetic preparation); THE

hydroxyalkyl, fluoroalkyl, etc., or when taken together represent the group  $-(CH_2)_x-$  where  $x$  is an integer from 2 to 5;  $R$  = any of the typical side chains known for vitamin D type compds.] are prepared These 2-substituted compds. are characterized by low intestinal calcium transport activity and high bone calcium mobilization activity resulting in novel therapeutic agents for the treatment of diseases where bone formation is desired, particularly low bone turnover osteoporosis. Thus, 20(S)-1 $\alpha$ ,25-dihydroxy-2-methylene-26,27-dihomo-19-nor-vitamin D<sub>3</sub> (II) was prepared via a multistep synthetic sequence starting from 20(S)-25-hydroxy Grundmann's ketone analog III and phosphine oxide IV. The intestinal calcium transport and serum calcium (bone calcium mobilization) activities in vitamin D-deficient rats on a low calcium diet responding to chronic doses of II at 15 pmol/day/7 days were  $4.0 \pm 0.4$  S/M and  $5.3 \pm 0.1$  S/M resp. These compds. also exhibit pronounced activity in arresting the proliferation of undifferentiated cells and inducing their differentiation to the monocyte thus evidencing use as anti-cancer agents and for the treatment of diseases such as psoriasis.

REFERENCE COUNT: 10 THERE ARE 10 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L10 ANSWER 25 OF 34 CAPLUS COPYRIGHT 2007 ACS on STN

ACCESSION NUMBER: 2002:332679 CAPLUS

DOCUMENT NUMBER: 136:335278

TITLE: 1 $\alpha$ -Hydroxy-2-methylene-19-nor-homopregnacalciferol and its therapeutic uses

INVENTOR(S): DeLuca, Hector F.; Sicinski, Rafal R.; Gowlugari, Sumithra; Plum, Lori A.; Clagett-Dame, Margaret

PATENT ASSIGNEE(S): USA

SOURCE: U.S. Pat. Appl. Publ., 14 pp., Cont.-in-part of U. S. Ser. No. 657,828.

CODEN: USXXCO

DOCUMENT TYPE: Patent

LANGUAGE: English

FAMILY ACC. NUM. COUNT: 2

PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
US 2002052350	A1	20020502	US 2001-878438	20010611
US 6440953	B2	20020827		
PT 1315504	T	20041231	PT 2001-942154	20010611
ES 2227215	T3	20050401	ES 2001-1942154	20010611
US 2002183289	A1	20021205	US 2002-165123	20020607
US 6579861	B2	20030617		

PRIORITY APPLN. INFO.: US 2000-657828 A2 20000908  
US 2001-878438 A3 20010611

IT 213250-70-5

RL: PAC (Pharmacological activity); BIOL (Biological study)  
(hydroxymethylenenorhomopregnacalciferol and therapeutic use)

RN 213250-70-5 CAPLUS


CN 19-Nor-9,10-secocholesta-5,7-diene-1,3,25-triol, 2-methylene-,  
(1 $\alpha$ ,3 $\beta$ ,7E,20S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.

Double bond geometry as shown.



QAZI



AB The invention discloses 1 $\alpha$ -hydroxy-2-methylene-19-nor-homopregnacalciferol and its pharmaceutical uses. This compound exhibits pronounced activity in arresting the proliferation of undifferentiated cells and inducing their differentiation to the monocyte thus evidencing use as an anti-cancer agent and for the treatment of skin diseases such as psoriasis as well as skin conditions such as wrinkles, slack skin, dry skin and insufficient sebum secretion. This compound also has little, if any, calcemic activity and therefore may be used to treat immune disorders in humans as well as renal osteodystrophy.

L10 ANSWER 26 OF 34 CAPLUS COPYRIGHT 2007 ACS on STN  
 ACCESSION NUMBER: 2002:71881 CAPLUS  
 DOCUMENT NUMBER: 136:112696  
 TITLE: Use of 2-methylene-19-nor-20(S)-1 $\alpha$ ,25-dihydroxyvitamin D3 to increase bone strength and for the treatment of skin disease, cancer, and bone disease  
 INVENTOR(S): Deluca, Hector F.; Smith, Connie M.  
 PATENT ASSIGNEE(S): Wisconsin Alumni Research Foundation, USA  
 SOURCE: PCT Int. Appl., 28 pp.  
 CODEN: PIXXD2  
 DOCUMENT TYPE: Patent  
 LANGUAGE: English  
 FAMILY ACC. NUM. COUNT: 1  
 PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2002005823	A2	20020124	WO 2001-US21706	20010710
WO 2002005823	A3	20020523		
W:	AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, UZ, VN, YU, ZA, ZW			
RW:	GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG			
CA 2416194	A1	20020124	CA 2001-2416194	20010710
AU 2001078888	A5	20020130	AU 2001-78888	20010710
EP 1301189	A2	20030416	EP 2001-957115	20010710
R:	AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR			
BR 2001012454	A	20030729	BR 2001-12454	20010710

10782337

QAZI

JP 2004505022	T	20040219	JP 2002-511755	20010710
NZ 537036	A	20060728	NZ 2001-537036	20010710
US 2004068129	A1	20040408	US 2003-673629	20030929
US 7115594	B2	20061003		
HK 1060304	A1	20060421	HK 2004-103322	20040512
US 2006135492	A1	20060622	US 2006-350554	20060209
US 2006135493	A1	20060622	US 2006-350555	20060209
PRIORITY APPLN. INFO.:			US 2000-616164	A 20000714
			WO 2001-US21706	W 20010710
			US 2003-673629	A3 20030929


IT 213319-29-0

RL: PAC (Pharmacological activity); BIOL (Biological study)  
(methylenenordihydroxyvitamin D3 to increase bone strength and for  
treatment of skin disease, cancer, and bone disease)

RN 213319-29-0 CAPLUS

CN 19-Nor-9,10-secocholesta-5,7-diene-1,3,25-triol, 2-methylene-,  
(1 $\alpha$ ,3 $\beta$ ,7E)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.  
Double bond geometry as shown.




IT 213250-70-5

RL: PAC (Pharmacological activity); THU (Therapeutic use); BIOL  
(Biological study); USES (Uses)  
(methylenenordihydroxyvitamin D3 to increase bone strength and for  
treatment of skin disease, cancer, and bone disease)

RN 213250-70-5 CAPLUS

CN 19-Nor-9,10-secocholesta-5,7-diene-1,3,25-triol, 2-methylene-,  
(1 $\alpha$ ,3 $\beta$ ,7E,20S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.  
Double bond geometry as shown.



AB The invention provides pharmaceutical uses for 2-methylene-19-nor-20(S)-

10782337

QAZI

1 $\alpha$ ,25-dihydroxyvitamin D3. This compound is characterized by high bone calcium mobilization activity demonstrating preferential activity on bone. This results in a novel therapeutic agent for the treatment of diseases where bone formation is desired, particularly osteoporosis. This compound also exhibits pronounced activity in arresting the proliferation of undifferentiated cells and inducing their differentiation to the monocyte, thus evidencing use as an anticancer agent and for the treatment of skin diseases such as psoriasis. This compound also increases both breaking strength and crushing strength of bones evidencing use in conjunction with bone replacement surgery such as hip and knee replacements.

L10 ANSWER 27 OF 34 CAPLUS COPYRIGHT 2007 ACS on STN

ACCESSION NUMBER: 2001:830900 CAPLUS

DOCUMENT NUMBER: 135:358086

TITLE: Preparation of 26,27-homologated-20-epi-2-alkyl-19-nor-vitamin D compounds

INVENTOR(S): Deluca, Hector F.; Sicinski, Rafal R.

PATENT ASSIGNEE(S): Wisconsin Alumni Research Foundation, USA

SOURCE: U.S., 33 pp., Cont.-in-part of U.S. Ser. No. 454,013.

CODEN: USXXAM

DOCUMENT TYPE: Patent

LANGUAGE: English

FAMILY ACC. NUM. COUNT: 6

PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
US 6316642	B1	20011113	US 2000-541470	20000331
US 5945410	A	19990831	US 1997-819694	19970317
US 6127559	A	20001003	US 1998-135463	19980817
US 6277837	B1	20010821	US 1999-454013	19991203
CA 2403232	A1	20011011	CA 2001-2403232	20010329
WO 2001074765	A1	20011011	WO 2001-US10094	20010329
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CR, CU, CZ, DE, DK, DM, DZ, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, UZ, VN, YU, ZA, ZW				
RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG				
EP 1268415	A1	20030102	EP 2001-920863	20010329
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR				
JP 2004500414	T	20040108	JP 2001-572460	20010329
NZ 521236	A	20051028	NZ 2001-521236	20010329
US 2002123638	A1	20020905	US 2001-999299	20011031
US 6544969	B2	20030408		
US 2003073857	A1	20030417	US 2002-246968	20020919
US 6667298	B2	20031223		
US 2004072804	A1	20040415	US 2003-673618	20030929
US 6939868	B2	20050906		
US 2004082802	A1	20040429	US 2003-683330	20031010
US 7112579	B2	20060926		
JP 2006096759	A	20060413	JP 2005-319359	20051102
PRIORITY APPLN. INFO.:			US 1997-819694	A2 19970317
			US 1998-135463	A3 19980817

10782337

QAZI

US 1999-454013	A2 19991203
JP 1998-540500	A3 19980211
US 2000-541470	A 20000331
WO 2001-US10094	W 20010329
US 2001-45941	B3 20011019
US 2001-999299	A3 20011031
US 2002-246968	A3 20020919

OTHER SOURCE(S): MARPAT 135:358086

IT 213319-29-0P

RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)


(preparation of 26,27-homologated-20-epi-2-alkyl-19-norvitamin D compds. with high intestinal calcium transport activity)

RN 213319-29-0 CAPLUS


CN 19-Nor-9,10-secocholesta-5,7-diene-1,3,25-triol, 2-methylene-, (1 $\alpha$ ,3 $\beta$ ,7E)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.

Double bond geometry as shown.



GI



AB 2-Alkyl-19-nor-vitamin D derivs. of formula I [Y<sub>1</sub>, Y<sub>2</sub> = H, protecting

10782337

QAZI

group; R = typical side chains known for vitamin D type compds.; R1 = alkyl, hydroxyalkyl, fluoroalkyl] are prepared. These 2-substituted compds., especially the 2 $\alpha$ -Me and the 2 $\alpha$ -methyl-20S derivs., are characterized by relatively high intestinal calcium transport activity and relatively high bone calcium mobilization activity resulting in novel therapeutic agents for the treatment of diseases where bone formation is desired, particularly low bone turnover osteoporosis. These compds. also exhibit pronounced activity in arresting the proliferation of undifferentiated cells and inducing their differentiation to the monocyte thus evidencing use as anticancer agents and for the treatment of diseases such as psoriasis. Thus, II was prepared and showed preferential activity on bone in biol. activity tests.

REFERENCE COUNT: 31 THERE ARE 31 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L10 ANSWER 28 OF 34 CAPLUS COPYRIGHT 2007 ACS on STN

ACCESSION NUMBER: 2001:747743 CAPLUS

DOCUMENT NUMBER: 135:288953

TITLE: Preparation of 2-alkylidene-19-nor-vitamin D compounds as antiosteoporotics and antitumor agents

INVENTOR(S): Deluca, Hector F.; Sicinski, Rafal R.

PATENT ASSIGNEE(S): Wisconsin Alumni Research Foundation, USA

SOURCE: PCT Int. Appl., 53 pp.

CODEN: PIXXD2

DOCUMENT TYPE: Patent

LANGUAGE: English

FAMILY ACC. NUM. COUNT: 3

PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2001074766	A1	20011011	WO 2001-US10317	20010329
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CR, CU, CZ, DE, DK, DM, DZ, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, UZ, VN, YU, ZA, ZW				
RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG				
US 6392071	B1	20020521	US 2000-540686	20000331
CA 2404548	A1	20011011	CA 2001-2404548	20010329
EP 1268416	A1	20030102	EP 2001-920897	20010329
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR				
JP 2003529581	T	20031007	JP 2001-572461	20010329
NZ 522160	A	20041126	NZ 2001-522160	20010329
PRIORITY APPLN. INFO.:			US 2000-540686	A 20000331
			US 1997-819693	A3 19970317
			US 1998-151113	A1 19980910
			US 1999-370966	B2 19990810
			WO 2001-US10317	W 20010329

OTHER SOURCE(S): MARPAT 135:288953

IT 213319-29-0P

RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses).

10782337

QAZI


(preparation of 2-alkylidene-19-nor-vitamin D compds. as antiosteoporotics and antitumor agents)

RN 213319-29-0 CAPLUS



CN 19-Nor-9,10-secocholesta-5,7-diene-1,3,25-triol, 2-methylene-,  
(1 $\alpha$ ,3 $\beta$ ,7E)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.

Double bond geometry as shown.



GI



AB Novel vitamin D related compds., namely, 2-alkylidene-19-nor-vitamin D derivs. of formula I [R1, R2 = H, protecting group; R3 = typical side chains known for vitamin D type compds.; R4, R5 = H, alkyl, hydroxyalkyl, fluoroalkyl, etc.; R4R5 = cycloalkylidene] are prepared These 2-substituted compds. are characterized by relatively high intestinal calcium transport activity and relatively high bone calcium mobilization activity resulting in novel therapeutic agents for the treatment of diseases where bone formation is desired, particularly low bone turnover osteoporosis. These compds. also exhibit pronounced activity in arresting the proliferation of undifferentiated cells and inducing their differentiation to the monocyte thus evidencing use as anticancer agents and for the treatment of diseases such as psoriasis. Thus, II is prepared and is found to be extremely potent

10782337

QAZI

in inducing differentiation of HL-60 cells.

REFERENCE COUNT: 5 THERE ARE 5 CITED REFERENCES AVAILABLE FOR THIS  
RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L10 ANSWER 29 OF 34 CAPLUS COPYRIGHT 2007 ACS on STN

ACCESSION NUMBER: 2001:747742 CAPLUS

DOCUMENT NUMBER: 135:304063

TITLE: Preparation of 26,27-homologated-20-epi-2-alkyl-19-nor-  
vitamin D compounds

INVENTOR(S): Deluca, Hector F.; Sicinski, Rafal R.

PATENT ASSIGNEE(S): Wisconsin Alumni Research Foundation, USA

SOURCE: PCT Int. Appl., 74 pp.

CODEN: PIXXD2

DOCUMENT TYPE: Patent

LANGUAGE: English

FAMILY ACC. NUM. COUNT: 6

PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2001074765	A1	20011011	WO 2001-US10094	20010329
W:	AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CR, CU, CZ, DE, DK, DM, DZ, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, UZ, VN, YU, ZA, ZW			
RW:	GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG			
US 6316642	B1	20011113	US 2000-541470	20000331
CA 2403232	A1	20011011	CA 2001-2403232	20010329
EP 1268415	A1	20030102	EP 2001-920863	20010329
R:	AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR			
JP 2004500414	T	20040108	JP 2001-572460	20010329
NZ 521236	A	20051028	NZ 2001-521236	20010329
US 2004072804	A1	20040415	US 2003-673618	20030929
US 6939868	B2	20050906		
PRIORITY APPLN. INFO.:			US 2000-541470	A 20000331
			US 1997-819694	A2 19970317
			US 1998-135463	A3 19980817
			US 1999-454013	A2 19991203
			WO 2001-US10094	W 20010329
			US 2001-45941	B3 20011019

OTHER SOURCE(S): MARPAT 135:304063

IT 213250-70-5P 213319-29-0P

RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT  
(Reactant or reagent)

(preparation of 26,27-homologated-20-epi-2-alkyl-19-nor-vitamin D compds. as  
antiosteoporotics and antitumor agents)

RN 213250-70-5 CAPLUS


CN 19-Nor-9,10-secocholesta-5,7-diene-1,3,25-triol, 2-methylene-,  
(1 $\alpha$ ,3 $\beta$ ,7E,20S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.

Double bond geometry as shown.

10782337

QAZI




RN 213319-29-0 CAPLUS


CN 19-Nor-9,10-secocholesta-5,7-diene-1,3,25-triol, 2-methylene-,  
(1 $\alpha$ ,3 $\beta$ ,7E)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.


Double bond geometry as shown.



GI



I



II

AB 2-Alkyl-19-nor-vitamin D derivs. of formula I [R1, R2 = H, protecting group; R3 = alkyl, hydroxyalkyl, fluoroalkyl; R4 = H, Me, acyl, OH, any of the typical side chains known for vitamin D type compds., etc.] are prepared

10782337



QAZI

These compds. are characterized by relatively high intestinal calcium transport activity and relatively high bone calcium mobilization activity resulting in novel therapeutic agents for the treatment of diseases where bone formation is desired, particularly low bone turnover osteoporosis. These compds. also exhibit pronounced activity in arresting the proliferation of undifferentiated cells and inducing their differentiation to the monocyte thus evidencing use as anti-cancer agents and for the treatment of diseases such as psoriasis. Thus, II is prepared and had a VDR binding ratio of 5.5, and HL-60 differentiation ED50 of 1.1 x 10<sup>-10</sup> M.

REFERENCE COUNT: 5 THERE ARE 5 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L10 ANSWER 30 OF 34 CAPLUS COPYRIGHT 2007 ACS on STN

ACCESSION NUMBER: 2000:699222 CAPLUS

DOCUMENT NUMBER: 133:267021

TITLE: preparation and therapeutic use of  
2-alkyl-19-nor-vitamin D derivatives

INVENTOR(S): Deluca, Hector F.; Sicinski, Rafal R.

PATENT ASSIGNEE(S): Wisconsin Alumni Research Foundation, USA

SOURCE: U.S., 27 pp., Cont.-in-part of U.S. 5,945,410.

CODEN: USXXAM

DOCUMENT TYPE: Patent

LANGUAGE: English

FAMILY ACC. NUM. COUNT: 6

PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
US 6127559	A	20001003	US 1998-135463	19980817
US 5945410	A	19990831	US 1997-819694	19970317
PT 971888	T	20040331	PT 1998-905101	19980211
ES 2206893	T3	20040516	ES 1998-905101	19980211
US 6277837	B1	20010821	US 1999-454013	19991203
US 6316642	B1	20011113	US 2000-541470	20000331
US 6306844	B1	20011023	US 2000-616778	20000714
US 2002151528	A1	20021017	US 2001-45941	20011019
US 2002123638	A1	20020905	US 2001-999299	20011031
US 6544969	B2	20030408		
US 2003073857	A1	20030417	US 2002-246968	20020919
US 6667298	B2	20031223		
US 2004072804	A1	20040415	US 2003-673618	20030929
US 6939868	B2	20050906		
US 2004082802	A1	20040429	US 2003-683330	20031010
US 7112579	B2	20060926		
US 2006003973	A1	20060105	US 2005-216951	20050831
JP 2006096759	A	20060413	JP 2005-319359	20051102
PRIORITY APPLN. INFO.:			US 1997-819694	A2 19970317
			JP 1998-540500	A3 19980211
			US 1998-135463	A3 19980817
			US 1999-454013	A2 19991203
			US 2000-541470	A3 20000331
			US 2000-616778	A3 20000714
			JP 2001-83085	A 20010322
			US 2001-45941	B3 20011019
			US 2001-999299	A3 20011031
			US 2002-246968	A3 20020919
			US 2003-673618	A3 20030929

10782337

QAZI

OTHER SOURCE(S): MARPAT 133:267021

IT 213250-70-5P

RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); RCT (Reactant); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); RACT (Reactant or reagent); USES (Uses)


(preparation and therapeutic use of 2-alkyl-19-nor-vitamin D analog)

RN 213250-70-5 CAPLUS

CN 19-Nor-9,10-secocholesta-5,7-diene-1,3,25-triol, 2-methylene-,  
(1 $\alpha$ ,3 $\beta$ ,7E,20S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.

Double bond geometry as shown.



IT 213319-29-0P

RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)


(preparation and therapeutic use of 2-alkyl-19-nor-vitamin D analog)

RN 213319-29-0 CAPLUS


CN 19-Nor-9,10-secocholesta-5,7-diene-1,3,25-triol, 2-methylene-,  
(1 $\alpha$ ,3 $\beta$ ,7E)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.

Double bond geometry as shown.



GI



AB This invention discloses a novel class of vitamin D related compds., namely, the 2-alkyl-19-nor-vitamin D derivs. (I) (Y1, Y2 = H, hydroxy-protecting group; R6 = alkyl, hydroxyalkyl, fluoroalkyl; R7 =  $\alpha$  or  $\beta$ -Me; Z = Y, -OY, -CH2OY, -C.tplbond.CY, -CH=CHY (Y = H, Me, -(CH2)m-C(R1R2)-(CH2)n-C(R3R4R5); where m and n, independently integers from 0-5; R1 = H, OH, protected hydroxy, F, CF3, alkyl etc., R2, R3, R4 = D, deuterioalkyl, H, F, CF3, alkyl etc., R1+R2 = O, =C(R2R3) etc., R5 = H, OH, protected hydroxy, alkyl, and wherein any of the CH-groups at position 20, 22, or 23 in the side chain may be replaced by a N atom or where any of the groups -CH(Me)-, -CH(R3)-, or -CH(R2)- at positions 20, 22, and 23, resp., may be replaced by an oxygen or sulfur atom)), were prepared Thus, I (Y1, Y2 = H; R6, R7 =  $\alpha$ -Me; Z = (CH2)3C(Me)2OH) (II) was prepared starting from Me quinicinate and followed by Wittig-Horner coupling with Grundman's ketone (III). The 2-substituted compds., especially the 2 $\alpha$ -Me and the 2 $\alpha$ -methyl-20S derivs., are characterized by relatively low intestinal calcium transport activity and high bone calcium mobilization activity resulting in novel therapeutic agents for the treatment of diseases where bone formation is desired, particularly low bone turnover osteoporosis. I also exhibit pronounced activity in arresting the proliferation of undifferentiated cells and inducing their differentiation to the monocyte thus evidencing use as anti-cancer agents and for the treatment of diseases such as psoriasis.

REFERENCE COUNT: 6 THERE ARE 6 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L10 ANSWER 31 OF 34 CAPLUS COPYRIGHT 2007 ACS on STN  
 ACCESSION NUMBER: 1999:505692 CAPLUS  
 DOCUMENT NUMBER: 131:144749  
 TITLE: Preparation of 14-epi-19-nor-vitamin D compounds with cell differentiation activity  
 INVENTOR(S): Paaren, Herbert E.  
 PATENT ASSIGNEE(S): Tetrionics, Inc., USA  
 SOURCE: U.S., 14 pp.  
 CODEN: USXXAM  
 DOCUMENT TYPE: Patent  
 LANGUAGE: English  
 FAMILY ACC. NUM. COUNT: 1  
 PATENT INFORMATION:


QAZI

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
US 5936105	A	19990810	US 1998-96330	19980611
PRIORITY APPLN. INFO.:			US 1997-53088P	P 19970613

IT 235108-14-2P  
 RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)  
 (preparation of 14-epi-19-nor-vitamin D compds. with cell differentiation activity)

RN 235108-14-2 CAPLUS  
 CN 19-Nor-9,10-secocholesta-5,7-diene-1,3,25-triol, 2-methylene-, (1 $\alpha$ ,3 $\beta$ ,7E,14 $\beta$ )- (9CI) (CA INDEX NAME)

Absolute stereochemistry.  
 Double bond geometry as shown.



AB 14-Epi-19-nor-vitamin D analog compds. are prepared with high cell differentiation and antiproliferative activity and low calcemic activity. More particularly, examples of such compds. include 14-epi-19-nor-1 $\alpha$ ,25-dihydroxyvitamin D3, 14-epi-20-epi-19-nor-1 $\alpha$ ,25-dihydroxyvitamin D3 (I), 14-epi-20-epi-19-nor-1 $\alpha$ -hydroxyvitamin D3, 14-epi-19-nor-1 $\alpha$ ,25-dihydroxyvitamin D2, 14-epi-19-nor-24-homo-1 $\alpha$ ,25-dihydroxyvitamin D3, 14-epi-19-nor-20(S)-hydroxymethyl-1 $\alpha$ -hydroxypregnacalciferol, and 14-epi-19-nor-20(R)-hydroxymethyl-1 $\alpha$ -hydroxypregnacalciferol. Thus, I was prepared and showed an EC50 of 0.66 nM to inhibit proliferation of HL-60 cells.

REFERENCE COUNT: 2 THERE ARE 2 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L10 ANSWER 32 OF 34 CAPLUS COPYRIGHT 2007 ACS on STN  
 ACCESSION NUMBER: 1998:672847 CAPLUS  
 DOCUMENT NUMBER: 130:52625  
 TITLE: New 1 $\alpha$ ,25-Dihydroxy-19-norvitamin D3 Compounds of High Biological Activity: Synthesis and Biological Evaluation of 2-Hydroxymethyl, 2-Methyl, and 2-Methylene Analogs  
 AUTHOR(S): Sicinski, Rafal R.; Prahl, Jean M.; Smith, Connie M.; DeLuca, Hector F.  
 CORPORATE SOURCE: Department of Biochemistry College of Agricultural and Life Sciences, University of Wisconsin-Madison, Madison, WI, 53706, USA  
 SOURCE: Journal of Medicinal Chemistry (1998), 41(23), 4662-4674  
 CODEN: JMCMAR; ISSN: 0022-2623

10782337

QAZI


PUBLISHER: American Chemical Society  
DOCUMENT TYPE: Journal  
LANGUAGE: English  
IT 213319-29-0P

RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); RCT (Reactant); SPN (Synthetic preparation); BIOL (Biological study); PREP (Preparation); RACT (Reactant or reagent) (synthesis and biol. evaluation of 2-hydroxymethyl, 2-Me, and 2-methylene 1 $\alpha$ ,25-dihydroxy-19-norvitamin D3 analogs)

RN 213319-29-0 CAPLUS

CN 19-Nor-9,10-secocholesta-5,7-diene-1,3,25-triol, 2-methylene-, (1 $\alpha$ ,3 $\beta$ ,7E)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.  
Double bond geometry as shown.



AB New highly active isomers of the natural hormone 1 $\alpha$ ,25-dihydroxyvitamin D3 possessing an exomethylene group at the 2-position were prepared in a convergent manner, starting with (-)-quinic acid and the corresponding (20R)- and (20S)-25-hydroxy Grundmann ketones. These 2-methylene-19-norvitamins were efficiently converted to the 2-Me and 2-hydroxymethyl derivs., some of which exhibited pronounced in vivo biol. activity. Configurations of the A-ring substituents were determined by 1H NOE difference spectroscopy as well as by spin decoupling expts. It was established that the bulky Me and hydroxymethyl substituents at C-2, due to their large conformational free energies, occupy mainly equatorial positions. Addnl., hydroxylation of the C(10)-C(19) double bond in 1 $\alpha$ ,25-(OH)<sub>2</sub>D3 was performed, resulting in 1 $\alpha$ ,19,25-trihydroxy-10,19-dihydrovitamin D3 derivs. in which the hydroxymethyl substituent at C-10, for steric reasons, is forced to occupy an axial position. In consequence, the vitamin D3 analogs were synthesized in which the 1 $\alpha$ -hydroxy group, required for biol. activity, is almost exclusively axially or equatorially oriented because of stabilization of the single A-ring chair conformations. The relative ability of the synthesized analogs to bind the porcine intestinal vitamin D receptor was assessed and compared with that of the natural hormone. It was established that vitamins possessing the axial orientation of the 1 $\alpha$ -hydroxy substituent exhibit a significantly increased receptor binding affinity. Compds. with a 2-methylene substituent showed selective calcemic activity profiles, being extremely effective on bone calcium mobilization. 2 $\alpha$ -Methyl-substituted vitamins proved to be much more active in vivo than the corresponding epimers with 2 $\beta$ -configuration. All of the 2-substituted vitamins exhibited pronounced HL-60 differentiating activity, those 2 $\alpha$ -substituted in the 20S-series being especially potent. The present studies imply that the axial orientation of the 1 $\alpha$ -hydroxy group is necessary for biol. activity of vitamin D

10782337

QAZI

comps.  
REFERENCE COUNT: 70 THERE ARE 70 CITED REFERENCES AVAILABLE FOR THIS  
RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L10 ANSWER 33 OF 34 CAPLUS COPYRIGHT 2007 ACS on STN  
ACCESSION NUMBER: 1998:635741 CAPLUS  
DOCUMENT NUMBER: 129:245333  
TITLE: Preparation of 2-alkylidene-19-nor-vitamin D compounds  
INVENTOR(S): Deluca, Hector F.; Sicinski, Rafal R.  
PATENT ASSIGNEE(S): Wisconsin Alumni Research Foundation, USA  
SOURCE: PCT Int. Appl., 61 pp.  
CODEN: PIXXD2  
DOCUMENT TYPE: Patent  
LANGUAGE: English  
FAMILY ACC. NUM. COUNT: 3  
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 9841501	A1	19980924	WO 1998-US2976	19980211
W: AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CU, CZ, DE, DK, EE, ES, FI, GB, GE, GH, GW, HU, IL, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, UA, UG, UZ, VN, YU, ZW				
RW: GH, GM, KE, LS, MW, SD, SZ, UG, ZW, AT, BE, CH, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CM, GA, GN, ML, MR, NE, SN, TD, TG				
US 5843928	A	19981201	US 1997-819693	19970317
CA 2283829	A1	19980924	CA 1998-2283829	19980211
CA 2283829	C	20060711		
AU 9862801	A	19981012	AU 1998-62801	19980211
AU 714253	B2	19991223		
EP 970047	A1	20000112	EP 1998-905102	19980211
EP 970047	B1	20020911		
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, FI				
NZ 337503	A	20000929	NZ 1998-337503	19980211
JP 2001504135	T	20010327	JP 1998-540501	19980211
JP 3786713	B2	20060614		
AT 223890	T	20020915	AT 1998-905102	19980211
ES 2179451	T3	20030116	ES 1998-905102	19980211
PT 970047	T	20030131	PT 1998-905102	19980211
NO 9904398	A	19990910	NO 1999-4398	19990910
NO 322535	B1	20061023		
JP 2006117680	A	20060511	JP 2005-319365	20051102
PRIORITY APPLN. INFO.:				A 19970317
				A3 19980211
				W 19980211
				WO 1998-US2976


OTHER SOURCE(S): MARPAT 129:245333  
IT 213250-70-5P  
RL: ADV (Adverse effect, including toxicity); BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)  
(preparation of 2-alkylidenenor-vitamin D comps.)  
RN 213250-70-5 CAPLUS  
CN 19-Nor-9,10-secocholesta-5,7-diene-1,3,25-triol, 2-methylene-

10782337

QAZI

(1 $\alpha$ ,3 $\beta$ ,7E,20S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.  
Double bond geometry as shown.



GI

\* STRUCTURE DIAGRAM TOO LARGE FOR DISPLAY - AVAILABLE VIA OFFLINE PRINT \*

AB The title compds. [I; Y1, Y2 = H, protecting group; R6, R8 = H, alkyl, hydroxyalkyl, fluoroalkyl, or R6R8 = (CH<sub>2</sub>)<sub>x</sub>; x = 2-5 integer; R = any of the typical side chains known for vitamin D type compds., e.g. Q] are prepared. Thus, 1 $\alpha$ ,25-dihydroxy-2-methylene-19-norvitamin D<sub>3</sub> (II) was prepared in 11 steps from (-)-quinic acid via tert-butyldimethylsilyl protection of the OH groups at the 3 and 5 positions, converting to protected quinic acid Me ester, oxidation of the 4-OH, methylenation using methyltriphenylphosphonium bromide, hydride reduction, NaIO<sub>4</sub> oxidation, condensation of 3,5-bis(tert-butyldimethylsilyloxy)-4-methylenecyclohexanone with Me<sub>3</sub>SiCH<sub>2</sub>-COOMe, DIBAL reduction, reaction with Ph<sub>2</sub>PH, H<sub>2</sub>O<sub>2</sub> oxidation, condensation with perhydroindanone III in the presence of BuLi, and deprotection. These 2-substituted compds. are characterized by low intestinal calcium transport activity and high bone calcium mobilization activity resulting in novel therapeutic agents for the treatment of diseases where bone formation is desired, particularly low bone turnover osteoporosis. The intestinal calcium transport and serum calcium (bone calcium mobilization) activities in rats responding to chronic doses of II at 130 pmol/day/7 days were 5.3 $\pm$ 0.4 S/M and 9.9 $\pm$ 0.2 mg/100 mL, resp., vs. 6.2 $\pm$ 0.4 S/M and 7.2 $\pm$ 0.5 mg/100 mL, resp., for 1,25-(OH)<sub>2</sub>D<sub>3</sub>. These compds. also exhibit pronounced activity in arresting the proliferation of undifferentiated cells and inducing their differentiation to the monocyte thus evidencing use as anti-cancer agents and for the treatment of diseases such as psoriasis.

REFERENCE COUNT: 4 THERE ARE 4 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L10 ANSWER 34 OF 34 CAPLUS COPYRIGHT 2007 ACS on STN  
ACCESSION NUMBER: 1998:635740 CAPLUS  
DOCUMENT NUMBER: 129:245332  
TITLE: Preparation of 2-alkyl-19-nor-vitamin D compounds and their biological activities  
INVENTOR(S): Deluca, Hector F.; Sicinski, Rafal R.  
PATENT ASSIGNEE(S): Wisconsin Alumni Research Foundation, USA  
SOURCE: PCT Int. Appl., 55 pp.

10782337

QAZI

DOCUMENT TYPE: Patent  
 LANGUAGE: English  
 FAMILY ACC. NUM. COUNT: 6  
 PATENT INFORMATION:


PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 9841500	A1	19980924	WO 1998-US2975	19980211
W: AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CU, CZ, DE, DK, EE, ES, FI, GB, GE, GH, GW, HU, IL, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, UA, UG, UZ, VN, YU, ZW				
RW: GH, GM, KE, LS, MW, SD, SZ, UG, ZW, AT, BE, CH, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CM, GA, GN, ML, MR, NE, SN, TD, TG				
US 5945410	A	19990831	US 1997-819694	19970317
CA 2272745	A1	19980924	CA 1998-2272745	19980211
CA 2272745	C	20051206		
AU 9862800	A	19981012	AU 1998-62800	19980211
AU 714390	B2	19991223		
EP 971888	A1	20000119	EP 1998-905101	19980211
EP 971888	B1	20031029		
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, FI				
BR 9808010	A	20000308	BR 1998-8010	19980211
NZ 337262	A	20000929	NZ 1998-337262	19980211
JP 2000513010	T	20001003	JP 1998-540500	19980211
JP 3786712	B2	20060614		
AT 253046	T	20031115	AT 1998-905101	19980211
PT 971888	T	20040331	PT 1998-905101	19980211
ES 2206893	T3	20040516	ES 1998-905101	19980211
NO 9904489	A	19990916	NO 1999-4489	19990916
NO 321925	B1	20060724		
US 2004072804	A1	20040415	US 2003-673618	20030929
US 6939868	B2	20050906		
JP 2006096759	A	20060413	JP 2005-319359	20051102
PRIORITY APPLN. INFO.:				US 1997-819694
				A 19970317
				JP 1998-540500
				A3 19980211
				WO 1998-US2975
				W 19980211
				US 2001-45941
				B3 20011019
OTHER SOURCE(S): MARPAT 129:245332				
IT 213250-70-5P 213319-29-0P				
RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)				
(preparation of 2-alkylnor-vitamin D compds. and their biol. activities)				
RN 213250-70-5 CAPLUS				
CN 19-Nor-9,10-secocholesta-5,7-diene-1,3,25-triol, 2-methylene-, (1 $\alpha$ ,3 $\beta$ ,7E,20S)- (9CI) (CA INDEX NAME)				

Absolute stereochemistry.  
 Double bond geometry as shown.

10782337




QAZI



RN 213319-29-0 CAPLUS

CN 19-Nor-9,10-secocholesta-5,7-diene-1,3,25-triol, 2-methylene-,  
(1 $\alpha$ ,3 $\beta$ ,7E)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.  
Double bond geometry as shown.



GI

\* STRUCTURE DIAGRAM TOO LARGE FOR DISPLAY - AVAILABLE VIA OFFLINE PRINT \*

AB The title compds. [I; Y1, Y2 = H, protecting group; R6 = alkyl, hydroxyalkyl, fluoroalkyl, etc.; R = any of the typical side chains known for vitamin D type compds., e.g. Q] are prepared. Thus, 1 $\alpha$ ,25-dihydroxy-2 $\alpha$ - and 1 $\alpha$ ,25-dihydroxy-2 $\beta$ -methyl-19-norvitamin D3 (II) were prepared in 11 steps from (-)-quinic acid via tert-butyldimethylsilyl protection of the OH groups at positions 3 and 5, converting to protected quinic acid Me ester, oxidation of the 4-OH, methylenation using methyltriphenylphosphonium bromide, hydride reduction, NaIO4 oxidation, condensation of the resulting 3,5-bis(tert-butyldimethylsilyloxy)-4-methylcyclohexanone with Me3SiCH2COOMe, DIBAL reduction, reaction with Ph2PH, oxidation, condensation with perhydroindanone

III in the presence of BuLi, and deprotection. These 2-substituted compds. are characterized by low intestinal calcium transport activity and high bone calcium mobilization activity resulting in novel therapeutic agents for the treatment of diseases where bone formation is desired, particularly low bone turnover osteoporosis. The intestinal calcium transport and serum calcium (bone calcium mobilization) activities in rats responding to chronic doses of II (both epimers) at 130 pmol/day/7 days

10782337

QAZI

were  $5.0 \pm 0.3$  S/M and  $6.1 \pm 0.1$  mg/100 mL, resp., vs.  $6.2 \pm 0.4$  S/M and  $7.2 \pm 0.5$  mg/100 mL, resp., for 1,25-(OH)<sub>2</sub>D<sub>3</sub>. These compds. also exhibit pronounced activity in arresting the proliferation of undifferentiated cells and inducing their differentiation to the monocyte thus evidencing use as anti-cancer agents and for the treatment of diseases such as psoriasis.

REFERENCE COUNT: 4 THERE ARE 4 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

=> S L10 AND AND delUCA

MISSING TERM 'AND AND'

The search profile that was entered contains a logical operator followed immediately by another operator.

=> S L10 AND DELUCA/AU

0 DELUCA/AU

L11 0 L10 AND DELUCA/AU

=> S L10 AND DELUCA

44 DELUCA

L12 0 L10 AND DELUCA

=> D HIS

(FILE 'HOME' ENTERED AT 13:30:52 ON 19 JAN 2007)

FILE 'REGISTRY' ENTERED AT 13:31:08 ON 19 JAN 2007

L1 1 S 235108-14-2/RN  
L2 1 S 213319-29-0/RN  
L3 0 S 2133250-70-5/RN  
L4 1 S 213250-70-5/RN

FILE 'CAPLUS' ENTERED AT 13:33:54 ON 19 JAN 2007

L5 0 S L1 AND L2 AND L4  
L6 1 S L1  
L7 29 S L2  
L8 48 S L4  
L9 27 S L7 AND L8  
L10 34 S L1 OR L2 OR L4 AND CANCER  
L11 0 S L10 AND DELUCA/AU  
L12 0 S L10 AND DELUCA

=> LOGOFF

ALL L# QUERIES AND ANSWER SETS ARE DELETED AT LOGOFF

LOGOFF? (Y)/N/HOLD:h

COST IN U.S. DOLLARS

SINCE FILE	TOTAL
ENTRY	SESSION
189.91	198.22

FULL ESTIMATED COST

DISCOUNT AMOUNTS (FOR QUALIFYING ACCOUNTS)

SINCE FILE	TOTAL
ENTRY	SESSION
-26.52	-26.52

CA SUBSCRIBER PRICE

SESSION WILL BE HELD FOR 120 MINUTES

STN INTERNATIONAL SESSION SUSPENDED AT 13:39:53 ON 19 JAN 2007

Connecting via Winsock to STN

10782337

QAZI

Welcome to STN International! Enter x:x

LOGINID:sssptal202sxq

PASSWORD:

\* \* \* \* \* RECONNECTED TO STN INTERNATIONAL \* \* \* \* \*  
SESSION RESUMED IN FILE 'CAPLUS' AT 13:41:11 ON 19 JAN 2007  
FILE 'CAPLUS' ENTERED AT 13:41:11 ON 19 JAN 2007  
COPYRIGHT (C) 2007 AMERICAN CHEMICAL SOCIETY (ACS)

COST IN U.S. DOLLARS	SINCE FILE	TOTAL
	ENTRY	SESSION
FULL ESTIMATED COST	189.91	198.22
DISCOUNT AMOUNTS (FOR QUALIFYING ACCOUNTS)	SINCE FILE	TOTAL
	ENTRY	SESSION
CA SUBSCRIBER PRICE	-26.52	-26.52

=> LOGOFF

ALL L# QUERIES AND ANSWER SETS ARE DELETED AT LOGOFF

LOGOFF? (Y)/N/HOLD:h

COST IN U.S. DOLLARS	SINCE FILE	TOTAL
	ENTRY	SESSION
FULL ESTIMATED COST	190.38	198.69
DISCOUNT AMOUNTS (FOR QUALIFYING ACCOUNTS)	SINCE FILE	TOTAL
	ENTRY	SESSION
CA SUBSCRIBER PRICE	-26.52	-26.52

SESSION WILL BE HELD FOR 120 MINUTES  
STN INTERNATIONAL SESSION SUSPENDED AT 13:41:31 ON 19 JAN 2007

10782337